MARK D. SULLIVAN, M.D., Ph.D.

Curriculum Vitae

Personal Data

Birthdate: August 5, 1955

Birthplace: Chicago, IL

Home 6801 17th Ave. NE

Address: Seattle, WA 98115

Office Department of Psychiatry & Behavioral Sciences

Address Box 356560,

 University of Washington

 Seattle, WA 98195-6560

Telephone: (206) 685-3184

Education

University of Michigan, Ann Arbor, MI

 B.S. in Neuroscience (High Honors and High Distinction), 1976

Washington University School of Medicine, St. Louis, MO, 1976-78

Vanderbilt University Graduate School

 M.A. in Philosophy 1982

 Ph.D. in Philosophy 1982

Vanderbilt University School of Medicine

 M.D. 1984

Postgraduate Training

Internship in Family Medicine, University of Missouri Hospital, Columbia, MO 1984-1985

Residency in Psychiatry, University of Washington Medical School, Seattle, WA 1985-1988

Faculty Positions

1988 to 1992 Acting Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington

1992 to 1995 Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington

1994 to 1995 Adjunct Assistant Professor, Medical History and Ethics, University of Washington, Seattle, Washington

1995 to 2002 Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington

1995 to 2002 Adjunct Associate Professor, Medical History and Ethics, University of Washington, Seattle, Washington

2002 to present Professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington

2002 to 2008 Adjunct Professor, Medical History and Ethics, University of Washington, Seattle, Washington

2008 to present Adjunct Professor, Bioethics and Humanities, University of Washington, Seattle, Washington

2011 to present Adjunct Professor, Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington

Hospital Positions

**Psychiatry Consultation-Liaison Service**

Setting: University of Washington Medical Center, Seattle, Washington

Service Chief: Ryan Kimmel, M.D.

Patient Population: Medical and surgical patients with psychiatric problems

Role: Attending physician for inpatient and outpatient consultations, supervising psychiatry residents and medical students

Liaison Clinics: Center for Pain Relief, Regional Heart Center

 Psychiatry attending on evenings and weekends for Emergency Room and Inpatient Service

Honors and Awards

University of Michigan, School of Literature, Science, and the Arts Scholarship, 1974-76

B.S. with High Honors and High Distinction 1976

Departmental Fellowship, Department of Philosophy, Vanderbilt University, 1978-82

Dissertation Research Grant, Vanderbilt University Graduate School, 1982

Sol W. Ginsburg Fellow of the Group for the Advance­ment of Psychiatry, 1987-1988

Laughlin Fellow of the American College of Psychiatrists, 1988

Sandoz Award for Academic Excellence, Psychiatry Residency, 1988

Ethel Ginsburg Post-Fellow of the Group for the Advancement of Psychiatry, 1989-1990

NIMH Research Career Development Award, K01, 1996-2001

Dorfman Journal Paper Award- honorable mention, Academy of Psychosomatic Medicine, 2000

Michael J. Cousins Foundation Visitor, Australia and New Zealand Faculty of Pain Medicine, 2005

University of Washington, Outstanding CME Faculty, 2010

Licensure to Practice

National Board of Medical Examiners Diplomate, 1985

State of Washington, 1985

Board Certified American Board of Psychiatry and Neurology, 1991 (#33951)

Professional Societies

American Pain Society

American Society for Bioethics and Humanities

Association for the Advancement of Philosophy and Psychiatry

International Association for the Study of Pain

Teaching

Curriculum Committee, Department of Psychiatry and Behavioral Sciences, UW1985-1988, 1994-1999

Admissions Committee, Department of Psychiatry, University of Washington, 1988-1990

Course Presentations in MHE #’s 411, 521, Medical History and Ethics, UW, 1986-present

Senior Resident Lectureship on Schizophrenia, Psychiatry/Behavioral Sciences, UW, 1987-88

Organized and Delivered Series on Ethics in Psychiatry to PGY-3 Residents, 1988-present

Psychosocial Rounds, bi-weekly lectures on psychiatry to general internal medicine residents, 1990-1993

Undergraduate Education Committee, Psychiatry & Behavioral Sciences, UW, 1992-1996

Coordination of PGY-3 Psychiatry resident didactics 1993-1999

Departmental Grand Rounds/CME Coordinator, 1998-2008

CME Courses: Office Mgmt Chronic Pain (’93, ’96, ’99, ’01, ’03, ’08,’10- present), Mental Health Update (’94, ’96, ’98,’00, Director: 2001-05), Summer Seminar in Health Care Ethics (yearly, 1991-present), Physical Medicine and Rehabilitation Board Review (’03-18), Family Medicine Update (’06, ’10, ‘16), Cardiovascular Nursing Update (’07, ‘09), The Challenge of Pain (2014-present)

Medical History and Ethics Advisory Committee on Clinical Ethics Education 2001-2005

Faculty Mentorship committees: Jesse Fann MD MPH, Victoria Harris, MD, MPH (chair), Ann Vanderstoep PhD, Lorin Gardner MD, Stephen Thielke MD MSPH, Eric Strachan, PhD

Research Mentorship: Michael Clark, Eamonn Swords, Paul Ciechanowski, Rich Biebuyck, Jagoda Pasic, Susan Bentley, Jennifer Braden, Allison Gullo, Catherine Howe, Dan Krashin

ISMS Mentorship: Michael Sornson, Heidi Summers, Karen Schilling, Soroush Mohandesi

Thesis committees: Deanna Dockter MN Thesis 2006, Sunil Aggarwal PhD Dissertation in Medical Geography 2007, Evelyn Pei-Fen Liu MN Thesis 2007, Alexa Meins PhD Dissertation in Nursing Sciences 2016

Special National Responsibilities

Member, Sub-committee on Psychiatric Aspects of Life-Sustaining Technology, American Psychiatric Association, 1992-94

Member, Group on Psychiatric Disorders in Int. Med., Society for General Internal Medicine, 1991-94

Executive Council, Association for the Advancement of Philosophy and Psychiatry, 1993-1996

Member, Ethics Task Force, Academy of Psychosomatic Medicine, 1993-1998

Special Reviewer, Behavioral Medicine Study Section, National Institute of Mental Health, 1995

Chair, Ethics Committee, American Pain Society, 2000-2006; Member, 1998-2008, 2013-present

Chair, Data Monitoring Board, Multi-Center Trial of Cognitive-Behavioral and Exercise Therapy for Gulf War Illness, VA Cooperative Studies, 1999-2001

Chair, HRQOL/CEA committee for ACCORD/ACCORDION Trial, NHLBI, 1999-present

Member, Data Monitoring Board, Collaborative Care for Anxiety in Primary Care, NIMH, 2000-2010

Editorial Board, American Pain Society Bulletin, 2002-2009

Editorial Board, *Pain,* 2003-10

Member, Industry Relations Task Force, American Pain Society, 2004-2005

Member, Committee on Ethical Issues, International Association for the Study of Pain, 2006-2010

Reviewer, American Heart Association, Pharmaceutical Roundtable Grants, 2006

Board Member, Western Pain Society 2007-2015

NHLBI Protocol Review Committee for the Systolic Blood Pressure Intervention Trial 2010-2011

American Heart Association Writing Committee, Importance of Self-reported Health Status, 2011

NHLBI Data Safety Monitoring Board, Ranolazine ICD-trial (RAID) 2011-2014

ACTTION-AAPT Pain Taxonomy Task Force, 2013-2016

FDA Opioid REMS Observational Studies Workgroup 2015-present

The Joint Commission, Pain Assessment and Management Technical Advisory Panel, 2016-17

American Pain Society, Pfizer/National Pain Strategy Grant Review Committee, 2016

Canadian National Opioid Guideline Expert Committee 2016-2017

American Academy of Pain Medicine, CDC opioid guideline review panel 2017-2018

ACTTION Opioid Taper Device Task Force 2018-present

IASP Definition of Pain Task Force Member 2018-present

VHA State of the Art Conference Pain and Opioids, Planning Committee 2018-2019

Special Local Responsibilities

Member, University of Washington Medical Center Ethics Advisory Committee, 1990-93, 1998-2013

Member, Ethics Consultation Service, 1993-2008

Member, UW Independent Studies-Medical Science (ISMS) Committee, 1994-1996

Faculty Senate Representative, Department of Psychiatry, University of Washington, 1996-1998

Member, End of Life Task Force, Washington State Medical Association, 1996

Member, Data Safety Monitoring Board, A controlled trial of sertraline for depression after traumatic brain injury, NCMRR, Bombardier and Fann PI’s. 2001-2006

Chair, Data Safety Monitoring Board, Randomized Trial of Treatment for Obesity and Depression, NIMH, Simon PI, 2003-2006

Member, University of Washington Medical Center End of Life Committee, 2001-2004

Member, Washington State Interagency Guideline on Opioid Dosing Panel, 2006-present

Member, University of Washington Continuing Medical Education Committee, 2007-2008

Member, Washington State Labor and Industries Physician Advisory Panel, 2007- 2013

Co-director, Behavioral Health Services, University of Washington Medical Center, Center for Pain Relief 2008-present

Medical Co-Director, UW Telepain, 2017-present

Washington Bree Collaborative Chronic Pain Collaborative Care Workgroup 2018-present

Editorial Boards

## Pain Medicine, Ethics Forum Editor

Research Funding

**"Disabling Tinnitus and Depression in the Elderly"**NIMH funding (RO1 AG08240-01)

$427,716 direct costs for three years 6/89-6/92
Principal Investigator: Mark D. Sullivan, 50% FTE

**"Physiological and Psychological Factors in Dizziness"**

Virginia Merrill Bloedel Hearing Research Center, $5,000, Research Affiliate

**"The Prevention of Cardiovascular Disability: The Role of Psychosocial Factors"**

American Heart Association funding (#91-WA-530)

$120,000 direct costs for three years 7/1/91 -6/30/94

Principal Investigator: Mark D. Sullivan, 20% FTE

**“Health Status and Service Use in Coronary Disease”**

NIMH funding (K01 MHO1351)

$653,168 direct costs for five years 2/01/97 – 1/31/02

Principal Investigator: Mark D. Sullivan, 70% FTE

**“Depression in End-Stage Heart Failure: Effects on Functional Status, Self-Care, and Health Care Utilization”**

American Heart Association Funding (9970185N)

$335,185 direct costs for three years 1/1/99-12/31/01

Principal Investigator: Mark D. Sullivan, 20% FTE

**“Depression in Heart Failure – Brain Body Interaction via Neurohormones, Cytokines and Chemokines”**

Charles A. Dana Foundation Funding

$100,000 direct costs for three years 7/1/99-6/30/01

Principal Investigator: Wayne Levy, MD

Co-Investigator: Mark D. Sullivan

**“Prevention of Cardiovascular Disease in Diabetes Mellitus—Clinical Center Network”**

NHLBI funding (NHLBI-HC-99-16)

$9,967,988 direct costs for nine years 1/01/99 – 03/31/10

Principal Investigator: Jeffrey L. Probstfield, MD

Co-investigator: Mark D. Sullivan, 10% FTE

**“ACCORD-MIND: Preventing Cognitive Decline in Patients with Type II Diabetes”**

National Institute of Aging, 4/1/03- 3/31/09

Principal Investigator: Jeffrey Williamson, MD

Co-investigator: Mark D. Sullivan, 10% FTE

#### “Psychosocial Factors in Silent Myocardial Ischemia”

American Heart Association, 1/1/04 – 12/31/06

$180,000 direct costs for three years

Principal investigator: Mark D. Sullivan, 20% FTE

**"Shared Decision-Making for Chronic Opioid Treatment"**

The Greenwall Foundation, 7/1/04- 6/30/05

$ 60,391 direct costs for 1 year

Principal investigator: Mark D. Sullivan, 20% FTE

**"A Single-Blind Placebo Run-in Trial of Venlafaxine for Activity-Limiting Osteoarthritis Pain"**

Wyeth Laboratories

$47,500 direct costs for 1 year

Principal investigator: Mark D. Sullivan, 10% FTE

**"A Single-Blind Placebo Run-in Trial of Duloxetine for Activity-Limiting Osteoarthritis Pain"**

Eli Lilly and Co.

$51,600 direct costs for 1 year

Principal investigator: Mark D. Sullivan, 10% FTE

 **“Shared Decision-Making in End-Stage Heart and Lung Disease”**

National Institute of Nursing Research, 9/1/04 – 8/31/06

$300,000 direct costs for two years

Principal investigator: Mark D. Sullivan, 30% FTE

**“Collaborative Opioid Prescribing Education”—website development**

Aetna Inc, Johnson & Johnson, Ortho McNeil 12-9-05 – 12-9-08

$150,000 direct costs for three years

Principal Investigator: Mark D. Sullivan, 10% FTE

**“Risks for Opioid Use and Abuse in Contrasting Chronic Pain Populations”**

National Institute on Drug Abuse 9-30-06 – 4-30-10

$912,140 direct costs for four years

Principal Investigator: Mark D. Sullivan, 30% FTE

**“Long-Term Opioid Management of Chronic Pain: Trends and Risks”**

National Institute on Drug Abuse 9-30-06 – 4-30-10

$2,311,331 direct costs for four years

Principal Investigator: Michael VonKorff

Co-investigator: Mark D. Sullivan, 15% FTE

**“Patient-Centered Disease Management for Advanced Heart Failure”**

VA Merit Review 7-1-08 – 6-30-11

 $450,000 direct costs for three years

 Principal Investigator: John Rumsfeld

 Co-investigator: Mark D. Sullivan, 10% FTE

**“COPE-N: Interactive education on opioid management of chronic pain for nurses”**

 National Institute on Drug Abuse 4-1-09 – 3-31-10

 $272,000 direct costs for one year

 Principal investigator: Mark D. Sullivan, 10% FTE

**“COPE-P: Shared Decision-Making Aid for Patients Regarding Chronic Opioid Therapy”**

 National Institute on Drug Abuse 7-15-10 – 7-14-11

 $262,635 direct costs for one year

 Principal investigator: Mark D. Sullivan, 10% FTE

**“Use and Abuse of Prescription Opioids among OEF/OIF Veterans”**

National Institute on Drug Abuse 7-15-10 – 7-14-14

$288,714 direct costs for four years

Co-investigator: Mark D. Sullivan, 10% FTE

**“Evaluation of the Washington State Guideline on Opioid Dosing for Chronic Pain**

Centers for Disease Control and Prevention 9/01/10- 8/31/12

$137,687 direct costs for two years

Co-Investigator: Mark D. Sullivan, 5% FTE

**“Development of Web-based Training in Chronic Opioid Therapy for FDA Opioid REMS”**

University of Washington Center for Commercialization 7/1/10 – 6/31/11

(UW C4C Project # 4272) $ 37,401

Principal Investigator: Mark D. Sullivan

**“Development of Web-based Tracking for Chronic Opioid Therapy in primary care”**

University of Washington Center for Commercialization 2/3/11- 8/1/11

(UW C4C Project # 45340) $ 6,400

Principal Investigator: Mark D. Sullivan

**“COPE 2.0 (Collaborative Opioid Prescribing Education 2.0)”**

Pfizer Medical Education Grants 10/1/11 – 9/30/12

(Pfizer Grant ID: 036886) $202,740

Principal Investigator: Mark D. Sullivan

**“PainTracker: Improving Clinicians’ Ability to Monitor Pain, Function and Opioid Dose in the Pacific Northwest Region”** 10/15/11 – 1/14/12

Pfizer Medical Education Grants

(Pfizer Grant ID: 038832) $29,740

Principal Investigator: Mark D. Sullivan

**Palliative care symptom management in rural communities** 11/1/11 – 4/30/14

National Institute of Nursing Research, R01 NR012450

Principal Investigator: Ardith Doorenbos, RN, PhD, $2,723,977

Co-investigator: Mark D. Sullivan, 5% FTE

**COPE-REMS: Educating Providers about Safe Opioid Prescribing** 2/1/12 – 1/31/13

Covidien Medical Education Grants

Covidien Grant ID# XXX $100,000

Principal Investigator: Mark D. Sullivan

**COPE-REMS: Mid-level Providers and Safe Opioid Prescribing** 2/1/13 – 8/31/13

Endo Medical Education Grants

Endo Grant ID# XXX $10,000

Principal Investigator: Mark D. Sullivan

**Pilot Randomized Trial of Opioid Taper Support** 09/15/2012 – 08/31/2016

National Institute on Drug Abuse, R34DA033384

Total Direct Costs over three years $418,500

Principal Investigator, Mark D. Sullivan

**Evaluation of the Washington State Guidelines on Opioid Dosing for Chronic Pain**

Centers for Disease Control and Prevention 9/1/2010-8/31/2013
(R21CE001850-01, $350,000)Principal investigator: Gary Franklin

Co-investigator: Mark Sullivan

**PainTracker: integrating a graphical outcome tool into the electronic medical record**

University of Washington Center for Commercialization 6/4/13- 12/4/13

(UW C4C Project # XXXX) $ 50,000

Principal Investigator: Mark D. Sullivan

**“COPE-REMS Training Program: Collaborative Opioid Prescribing Education-REMS Training”**

FDA ER/LA Opioid Analgesics REMS Program Companies (RPC) 12/1/13 – 11/30/14

(EG-000228, $799,577 )

Principal Investigator: Mark D. Sullivan

**“COPE-REMS Training Program: Phase 2”**

FDA ER/LA Opioid Analgesics REMS Program Companies (RPC) 12/1/14 – 11/30/15

(EG-000269, $785,400 )

Principal Investigator: Mark D. Sullivan

**Improving the Quality of Care for Pain and Depression in Persons with Multiple Sclerosis**

Patient-Centered Outcomes Research Institute PCORI 10/01/13 - 09/30/16

(IH-1304-6379, $2,094,477)

Principal Investigator: Dawn Ehde

Co-investigator: Mark Sullivan

**PainTracker Self-Manager: a web-based platform to promote chronic pain self-management and track treatment outcomes** 9/1/15 – 8/31/17

Pfizer Independent Grants for Learning & Change # 19561405,

Total direct costs over 2 years $696,977.

Principal Investigator: Mark D. Sullivan

**Facilitating Lower Opioid Amounts Through Tapering** 5/1/17 – 4/30/20

National Institute on Drug Abuse, R01 DA042124-01A1

Total direct costs over 3 years: $991,342

Principal Investigator: David Smith

Co-investigator: Mark Sullivan

**The effect of primary care opioid taper plans and their components on sustained opioid taper and opioid discontinuation 1/1/18 -12/31/18**

Purdue Pharma # R216179001

Total direct costs over one year: $336,354

Principal investigator: Mark Sullivan

**Randomized trial of telephonic pain self-management to promote opioid tapering 10/1/18 – 9/30/22**

National Institute on Drug Abuse, R01 DA044970

Total direct costs over 4 years $1,748,095

Principal investigator: Mark D. Sullivan

**Comparative effectiveness of Washington and Ohio opioid review programs 1/1/19 – 12/31/22**

Patient-Centered Outcomes Research Institute (PCORI) UOP-2017C2-8509

Total direct costs over 3 years: $4,978,167

Role: Co-investigator

**Pathways from Chronic Prescription Opioid Use to New Onset Mood Disorder 04/15/19 – 1/31/24**

National Institute on Drug Abuse R01DA043811-01A1

 Total direct costs over 4.75 years: $3,155,664

 Role: Co-investigator

**BIBLIOGRAPHY (As of 5-14-19, overall 44873 citations, h-index= 85)**

**NCBI bibliography available at:**

<https://www.ncbi.nlm.nih.gov/myncbi/1Nu-7wf1yHGQ3/bibliography/public/>

Original Publications

1. **Sullivan MD**: Mechanism and ritual: failures of scientific medicine in primary care. *New Physician* 15:55-56, 1979.

2. **Sullivan MD**: In what sense is contemporary medicine dualistic? *Culture Med Psychiatry* 10:331-350, 1986.

3. **Sullivan MD**: Body-snatching: Medicine and the Cartesian threat. *Jefferson J Psychiatry* 4:2:51-61, 1986.

4. **Sullivan M**, Katon W, Dobie R, Sakai C, Russo J, Harrop-Griffths: Disabling Tinnitus: association with affective disorder. *Gen Hosp Psychiatry* 10:285-291, 1988.

5. **Sullivan MD**. Dobie RA, Sakai CS, Katon W: Treatment of depressed Tinnitus patients with nortriptyline. *Ann Otology Rhinology Laryngology* 98:867-872, 1989.

6. Katon WJ and **Sullivan MD**: Depression and chronic medical illness. *J Clin Psychiatry* 51 (Suppl 6): 3-14, 1990.

7. **Sullivan MD**: Organic or functional?: why psychiatry needs a philosophy of mind. *Psychiatric Ann* 20:271-277, 1990.

8. **Sullivan MD**: Reconsidering the wisdom of the body: an epistemological critique of Claude Bernard's concept of the internal environment. *J Med Philosophy* 15:493-514, 1990.

9. **Sullivan MD**, Turner JF, Romano JM: Chronic pain in primary care: identification and management of psychosocial factors. *J Fam Pract* 32:193-199, 1991.

10. **Sullivan MD**: Multidisciplinary treatment of a woman with chronic hand pain.  *Hosp Community Psychiatry* 42:474-475, 1991.

11. **Sullivan MD**, Ward NG, Laxton A: The woman who wanted ECT and DNR: questions of competence on a medical-psychiatric unit.  *Gen Hosp Psychiatry* 14:204-209, 1992.

12. Dobie RA, **Sullivan MD**, Katon WJ, Sakai CS, Russo J: Antidepressant treatment of Tinnitus patients: interim report of a randomized clinical trial *Acta Oto-Laryngologica*  112:242-247, 1992.

13. **Sullivan MD**, Katon W, Russo J, Dobie RA, Sakai CS: Somatization, co-morbidity, and the quality of life: measuring the effect of depression on chronic medical illness.  *Psychiatric Med* 10:61-76, 1992.

14. **Sullivan MD**, Loeser JD: The diagnosis of disability: treating and rating disability in a pain clinic. *Arch Intern Med* 152:1829-1835, 1992.

15. Katon WJ, **Sullivan MD**, Russo J, Dobie RA, Sakai CS: Depressive symptoms and measures of disability: a prospective longitudinal study. *J Affect Dis* 27:245-254, 1993.

16. **Sullivan MD**: Michel Foucault and the truth of madness. *Rev Existential Psychiatry Psychology* 21:81-96, 1993.

17. **Sullivan MD**: Placebo controls and epistemic control in orthodox medicine. *J Med Philosophy* 18:213-231, 1993.

18. Dobie RA, Sakai CS, **Sullivan MD**, Katon WJ, Russo J: Antidepressant treatment of Tinnitus patients: report of a randomized clinical trial and clinical prediction of benefit. *Am J Otology* 14:18-23, 1993.

19. **Sullivan MD**, Verhulst JV, Russo J, Roy-Byrne PP: Pharmacotherapy vs. psychotherapy: are psychiatrists polarized? *Am J Psychother* 47:411-423, 1993.

20. **Sullivan MD**, Clark MR, Katon WJ, Russo JE, Fischl M, Dobie RA, Voorhees R: Psychiatric and otologic diagnoses in patients complaining of dizziness. *Arch Intern Med* 153:1479-1484, 1993.

21. Wingerson D, **Sullivan M**, Dager S, Flick S, Dunner D, Roy-Byrne P: Personality predictors of early discontinuation from psychopharmacology trials. *J Clin Psychopharm* 13:194-197, 1993.

22. **Sullivan MD**, Toshima M, Lynn P, Roy-Byrne PP: Clonazepam vs. Phenobarbital for sedative-hypnotic taper in chronic pain patients. *Ann Clin Psychiatry* 5:123-128, 1993.

23. **Sullivan MD**, Katon WJ, Russo J, Dobie RA, Sakai CS: A randomized trial of nortriptyline in chronic severe Tinnitus: effects on depression, disability and symptoms. *Arch Intern Med* 153:2251-2259, 1993.

24. Clark MR, **Sullivan MD**, Katon WJ, Russo JE, Fischl M, Dobie RA, Voorhees R: Psychiatric and medical factors associated with disability in patients with dizziness. *Psychosomatics* 34:409-415, 1993.

25. **Sullivan MD**, Katon WJ: Somatization: the path from distress to somatic symptoms. *APS Journal* 2:141-149, 1993.

26. Logue MB, Thomas AM, Barbee JG, Hoehn-Saric R, Maddock RJ, Schwab J, Smith RD, **Sullivan M**, Beitman BD: Generalized anxiety disorder patients seek evaluation for cardiological symptoms at the same frequency as patients with panic disorder. *J Psychiatric Res* 27:55-59, 1993.

27. Walker E, **Sullivan M**, Stenchever M: Antidepressant treatment of chronic pelvic pain*. Obstet Gyn Clin North Am* 20:743-752, 1993.

28. **Sullivan MD**: Psychosomatic clinic or pain clinic: which is more viable? *Gen Hosp Psychiatry* 15:375-380, 1993.

29. Roy-Byrne PP, **Sullivan MD**, Cowley DS, Ries RK: Adjunctive treatment of benzodiazepine discontinuation syndromes: a review. *J Psychiatric Res* 27:143-153, 1993.

30. **Sullivan MD**, Katon WJ, Russo JR, Dobie RA, Sakai CS: Coping and marital support as correlates of Tinnitus disability. *Gen Hosp Psychiatry* 16:259-266, 1994.

31. Clark MR, **Sullivan MD**, Fischl M, Katon WJ, Russo JE, Dobie RA, Voorhees RD: Symptoms as a clue to otologic and psychiatric diagnoses in patients with dizziness. *J Psychosom Res* 38:461-470, 1994.

32. **Sullivan MD**, Youngner SJ: Depression, competence and the right to refuse life-saving treatment. *Am J Psychiatry* 151:971-978, 1994.

33. Russo JR, Katon WJ, **Sullivan MD**, Buchwald DR: Severity of somatization: relation to psychiatric disorders and personality. *Psychosomatics* 35:546-556, 1994.

34. **Sullivan MD**: Depression and health care utilization. *Diabetes Spectrum* 7:181-182, 1994

35. Culver C, Moor J, Duerfeldt W, Kapp M, **Sullivan M**: Medical privacy. *Professional Ethics* 3:3-25, 1994.

36. **Sullivan MD**: Depression and disability from chronic medical illness.  *Eur J Public Health* 5(1):40-45, 1995.

37. Cole SA, **Sullivan MD**, Kathol R, Warshaw C: A model curriculum for mental disorders and behavioral problems in primary care.  *Gen Hosp Psychiatry* 17:13-18, 1995.

38. **Sullivan MD**: Pain in language: from sentience to sapience.  *Pain Forum* 4:1-11, 1995.

39. **Sullivan MD**: Uniquely human pain: a biocultural phenomenon.  *Pain Forum* 4:25-6, 1995.

40. Loeser JD, **Sullivan MD**: Disability in the chronic low back pain patient may be iatrogenic. *Pain Forum* 4(2):114-121, 1995.

41. Loeser JD, **Sullivan MD**: On sorting out the crocks. *Pain Forum* 4(2):132-133, 1995.

42. **Sullivan MD**: The history of psychiatric theories becomes self-aware. *Curr Opin Psychiatry* 8:351-353, 1995.

43. **Sullivan MD**: Key concepts: pain. *Philosophy, Psychiatry and Psychology* 2(3):277-280, 1995

44. **Sullivan MD**, Cohen-Cole SA, Gordon G, Hahn S, Kathol R: Psychiatric training in medicine residencies: current needs, practices and satisfaction. *Gen Hosp Psychiatry* 18:95-101, 1996.

45. Zaubler T, **Sullivan M**: Psychiatry and physician-assisted suicide*. Psychiatric Clin North Am* 19:413-427, 1996.

46. **Sullivan MD**, LaCroix AX, Baum C, Resnick A, Grothaus L, Pabiniak C, Katon W, Wagner E: Coronary disease severity and functional impairment: how strong is the relation? *J Am Geriatr Soc* 44:1461-1465, 1996.

47. **Sullivan MD**: Pain as emotion.  *Pain Forum* 5:208-209, 1996.

48. Katon W, **Sullivan M**: Of healing and human suffering. *J Am Brd Fam Pract* 10(1):62-65, 1997.

49. Loeser J, **Sullivan MD**: Doctors, diagnosis and disability: a disastrous diversion. *Clin Ortho* 336:61-66, 1997.

50. **Sullivan MD**, Rapp S, Fitzgibbon D, Chapman CR: Pain and the choice to hasten death among patients with painful metastatic cancer. *J Palliative Care* 13:3;18-28, 1997.

51. Walker E, Katon W, Keegan D, Gardner G, **Sullivan M**: Predictors of physician frustration in the care of patients with rheumatological complaints. *Gen Hosp Psychiatry* 19:315-323, 1997.

52. Jung AJ, Staiger T, **Sullivan MD**: The efficacy of selective serotonin-reuptake inhibitors for the management of chronic pain: a review. *J Gen Intern Med* 12:384-389, 1997.

53. Walker E, Keegan D, Gardner G, **Sullivan M**, Bernstein D**,** Katon W:Psychosocial factors in fibromyalgia and rheumatoid arthritis I. Psychiatric diagnosis and functional disability.  *Psychosom* *Med* 59:565-571, 1997.

54. Walker E, Keegan D, Gardner G, **Sullivan M**, Katon W, Bernstein D: Psychosocial factors in fibromyalgia and rheumatoid arthritis II. Sexual, physical and emotional abuse and neglect*. Psychosom* *Med* 59:572-577, 1997*.*

55. **Sullivan MD**, LaCroix AX, Baum C, Grothaus L, Katon W: Functional status in coronary artery disease: a one-year prospective study of the role of anxiety and depression. *Am J Med* 103:331-338, 1997.

56. **Sullivan MD**: Maintaining good morale in old Age. *West J Med* 167:276-284, 1997.

57. **Sullivan MD**: Treatment of depression at the end of life: clinical and ethical aspects. *Sem Clin Neuropsychiatry* 3:151-156, 1998.

58. **Sullivan M**, Ganzini L, Youngner SJ: Should psychiatrists be gatekeepers for assisted suicide? *Hastings Center Rep* 28(4): 24-31, 1998*.*

59. **Sullivan MD**, LaCroix AX, Russo JE, Katon WJ: Self-efficacy and self-reported functional status in coronary heart disease: a six-month prospective study. *Psychosom Med* 60:473-478, 1998.

60. **Sullivan MD**, Ormel J, Kempen GIJM, Tymstra T: Beliefs concerning death, dying, and hastened death in functionally impaired Dutch elderly: a one year prospective study. *J Am Geriatr Soc* 46:1241-1246, 1998.

61. **Sullivan M**, The Problem of pain in the clinico-pathological method. *Clin J Pain* 14:196-201, 1998.

62. Unützer J, Katon W, **Sullivan MD**, Miranda J. Treating depressed older adults in primary care: narrowing the gap between efficacy and effectiveness. *Milbank Quart* 77(2):225-256, 1999.

63. **Sullivan MD**. Chronic pain: The need for a “second-person” account. *Sem Clin Neuropsychiatry* 4(3):195-202, 1999.

64. **Sullivan MD**: Does Psychiatry need the Husserlian detour? *J Consciousness Stud* 6 (2-3):296-298, 1999.

65. **Sullivan M**, LaCroix A, Swords E, Sornson M, Russo J, Katon W. Depression in coronary heart disease: what is the appropriate diagnostic threshold? *Psychosomatics* 40(4):286-292, 1999.

*[2000 Dorfman Journal Paper Award- honorable mention, Academy of Psychosomatic Medicine]*

66. Barrett JE, Williams JW, Oxman TE, Katon W, Frank E, Hegel MT, **Sullivan M**, Schulberg HC: The treatment effectiveness project: A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia. Background and research plan. *Gen Hosp Psychiatry* 21:260-273, 1999.

67. Kempen GIJM, **Sullivan MD**, van Sonderen E, Ormel J: Performance-based and self-reported physical function in low-functioning older persons: synchrony of change and the impact of depressive symptoms. *J Gerontol Psychiatric Sci* 54B:380-386, 1999.

68. **Sullivan MD**, DSM-IV Pain Disorder: a case against the diagnosis. *Int Rev Psychiatry* 12:91-98, 2000.

69. Williams Jr JW, Barrett J, Oxman T, Frank E, Katon W, **Sullivan M**, Cornell J, Sengupta A: Treatment of dysthymia and minor depression in primary care: a randomized trail in older adults comparing placebo, paroxetine and problem solving therapy. *JAMA* 284:1519-1526, 2000.

70. **Sullivan MD**, LaCroix A, Spertus J, Hecht J: A 5 year prospective study of the role of anxiety and depression in patients with coronary heart disease. *Am J Cardiology* 86:1135-1140, 2000.

71. **Sullivan MD**, Kempen GIJM, Van Sonderen E, Ormel J: Models of health-related quality of life in a population of community-dwelling Dutch elderly. *Qual Life Res* 9: 801-810, 2000.

72. **Sullivan MD**: Ethical principles in pain management. *Pain Med* 1:274-279, 2000.

73. Katon WJ, **Sullivan MD**, Walker EA: Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, personality traits. *Ann Intern Med* 134:917-925, 2001.

74. **Sullivan MD**, Spertus JA: Chest pain: cause and consequence of coronary artery bypass grafting? *Pain* 92:1-4, 2001.

75. Ferrell BR, Novy D, **Sullivan MD**, Banja J, Dubois M Gitlin M, Hamaty D, Lebovitz A, Lipman AG, Lippe PM, Livovich J: Ethical dilemmas in pain management. *J Pain* 2:171-180, 2001.

76. **Sullivan MD**: Finding pain between minds and bodies. *Clin J Pain* 17:146-156, 2001.

77. Nazemi H, Larkin A, **Sullivan M**, Katon W: Methodological issues in recruitment strategies for patients with depression in primary care*. Int J Psychiat* *Med* 31:277-288, 2001.

78. **Sullivan MD**, LaCroix AX, Russo JE, Walker EA. Depression and self-reported physical health in Patients with coronary disease: mediating and moderating factors. *Psychosom Med* 63:248-256, 2001.

79. Frank E, Rucci P, Katon W, Barrett J, Williams Jr JW, Oxman T, **Sullivan M**, Cornell J: Correlates of response to treatment in primary care patients with minor depression. *Gen Hosp Psychiatry* 24:12-19, 2002.

80. Katon W, Russo J, Frank E, Barrett J, Williams Jr. JW, Oxman T, **Sullivan M**, Cornell J: Predictors of nonresponse to treatment in primary care patients with dysthymia. *Gen Hosp Psychiatry* 24:20-27, 2002.

81. Carter GT, **Sullivan MD**: Antidepressants in pain management. *Curr Opin Investig Drugs* 3:454-458, 2002.

82. **Sullivan MD**: The illusion of patient choice in end-of-life care. *Am J Geriatr Psych* 10:1-8, 2002.

83. Schmaling KB, Dimidjian S, Katon W, **Sullivan M**: Response styles among patients with minor depression and dysthymia in primary care. *J Abn Psychology* 111:350-356, 2002.

84. **Sullivan MD**, Simon GE, Spertus JA, Russo JE: Depression-related costs in heart failure care. *Arch Int Med* 162:1860-1866, 2002.

85. Ormel J, **Sullivan M**, Kempen G, Rijsdijk F, van Sonderen E: Temporal and reciprocal relationships between (I)ADL-disability and depressive symptoms in late life. *J Gerontology* 57:338-347, 2002.

86. Chwastiak L, Ehde DM, Gibbons LE, **Sullivan MD**, Bowen JD, Kraft GH: Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. *Am J Psychiatry* 159 1862-1868, 2002.

87. **Sullivan MD:** Book review: Horwitz, A. *Creating Mental Illness. JAMA*  289:234-235, 2002.

88. **Sullivan MD**, The meaning of facial expressions of pain lies in their use, not their reference. *Behav Brain Sci***,** 25:472-3, 2002

89. **Sullivan MD**, Katon WJ, Russo JE, Frank E, Barrett J, Oxman T, Williams J: Predictors of response to paroxetine and placebo among primary care patients with dysthymia and minor depression. *J Am Board Fam Pract* 16:22-31, 2003.

90. **Sullivan MD**, LaCroix A, Spertus J, Hecht J: Depression predicts revascularization procedures for five years after coronary angiography. *Psychosom Med* 65:229-236, 2003.

91. Pasic J, Levy WC, **Sullivan MD**: Cytokines in depression and heart failure. *Psychosom Med* 65:181-193**,** 2003.

92. **Sullivan MD**: The new subjective medicine: taking the patient’s point of view on health and health care. *Soc Sci Med* 56:1595-1604, 2003.

# 93. **Sullivan MD**: Hope and hopelessness at the end of life. *Am J Geriatr Psychiatry* 11:393-405, 2003.

# 94. Mitchell SH, Steele NP, Leclerc KM, **Sullivan MD**, Levy WC: The oxygen cost/watt of exercise is increased in heart failure when recovery costs are accounted for. *Chest,* 2003; 124:572-9

# 95. Ciechanowski P, **Sullivan MD**, Jensen M, Romano J, Summers H: Attachment style in chronic pain patients: the relation of attachment style to depression, catastrophizing and health care utilization. *Pain,* 2003; 104:627-638

# 96. Staiger T, Gaster B, **Sullivan M**, Deyo R: A systematic review of antidepressants for the treatment of low back pain*. Spine*, 2003; 28:2540-2545

97. Ehde DM, Gibbons LE, Chwastiak L, Bombardier CH, **Sullivan MD**, Kraft GH: Chronic pain in a large community sample of persons with multiple sclerosis. *Multiple Sclerosis*, 2003; 9:605-611

# 98. **Sullivan MD**, Newton KA, Hecht JA, Russo JE, Spertus JA: Depression and health status in elderly patients with heart failure: a 6-month prospective study in primary care. *Am J Geriat Cardiol,* 2004; 13:252-60.

# 99. **Sullivan MD**, Levy WC, Russo JE, Spertus JA. Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. *J Cardiac Failure,* 2004; 10:390-6.

100. **Sullivan MD,** Placebos and treatment of pain, *Pain Medicine,* 2004; 5:325-6

101. **Sullivan MD**: Exaggerated pain behavior: by what standard? *Clin J Pain*, 2004; 20:433–439

102. Dudzinski DM, **Sullivan MD**, When Agreeing with the Patient’s Decision is not enough: a schizophrenic woman requests pregnancy termination, *Gen Hosp Psychiatry,* 2004; 26:475-80.

103. **Sullivan MD**, Levy WC, Crane BA, Russo JE, Spertus JA, Usefulness of depression to predict time to combined endpoint of transplant or death for out-patients with advanced heart failure, *Am J Cardiol,* 2004; 94:1577-80

104.Pasic J, **Sullivan MD,** Russo JE, Chandler W, Levy WC**,** Lack of depression effect on platelet activation in patients with heart failure, *Psychiatry Research,* 2004; 129: 289– 292

105.

106. **Sullivan M**, Terman GW, Peck B, Correll DJ, Rich B, Clark WC, Latta K, Lebovits A, Gebhart G APS position statement on the use of placebos in pain management. J Pain. 2005; 6:215-7.

107. Huehnergarth K, Mozaffarian D, **Sullivan MD**, Crane BA, Wilkinson C, Lawler RL, McDonald GB, Fishbein DP, Levy WC, Relative Lymphocyte Count is an Independent Predictor of Mortality/Urgent Transplant in Heart Failure, *Am J Cardiol;* 2005; 95:1492–1495

108. **Sullivan MD**, The desire for death arises from an intolerable future rather than an intolerable present, *Gen Hosp Psychiat,* 2005; 27:256-7

109.Rumsfeld JS, Jones PG, Whooley MA, **Sullivan MD**,Pitt B,Weintraub WW,Spertus JA, Depression Predicts Mortality and Hospitalization In Patients With Heart Failure After Myocardial Infarction, *Am Heart J,* 2005;150:961-7

110.Chwastiak LA, Gibbons LE, Ehde DM, **Sullivan MD**, Bowen JD, Bombardier CH, Kraft GH, Fatigue and Psychiatric Illness in a Large Community Sample of Persons with Multiple Sclerosis, *J Psychosom Res,* 2005; 291– 298

# 111. **Sullivan MD**, Edlund ME, Steffick D, Unutzer J, Regular Use of Prescribed Opioids: association with common psychiatric disorders, *Pain,* 2005; 119:95–103

112. **Sullivan MD,** Leigh J, Gaster B, Training Internists in shared decision-making about chronic opioid treatment for non-cancer pain. *J Gen Int Med*  2006; 21:360-2

113.  **Sullivan MD**, Robinson JP, Antidepressant and anticonvulsant medications in the treatment of chronic pain, *Physical Medicine and Rehabilitation Clinics of North America,* 2006; 17:381-400

114. **Sullivan MD,** O’Meara E, Heart failure at the end of life: symptoms, function and medical care from the Cardiovascular Health Study. *Am J Geriat Cardiol,.* 2006; 15:217-25.

115. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, **Sullivan MD**, Pitt B, Poole-Wilson PA, Mann DL, Packer M, The Seattle Heart Failure Score: An individualized prediction of survival in heart failure, C*irculation,* 2006; 113:1424-33

116. **Sullivan MD**, Mason L, Slowly dying from sarcoidosis: a patient’s narrative of hanging on and letting go, *J Palliative Care*, 2006; 22:119-123

117. **Sullivan MD**, Edlund MJ, Chang L, Unutzer J, Wells KB, Association between mental health disorders, problem drug use, and regular prescription opioid use, *Arch Intern Med*. 2006; 166:2087-93

118. Lin EHB, Tang L, Katon W, Hegel M, **Sullivan MD**, Unutzer J, Arthritis Pain and Disability: Response to Collaborative Depression Care, *Gen Hosp Psychiatry,* 2006; 28:482-486

# 119. **Sullivan MD,** Anderson R, Aron D, Atkinson H, Bastien A, Chen J, Feeney P, Gafni A, Katz L, Narayan KMV, Nwachuku C, O’Connor, Design of Health-related Quality of Life and Cost-effectiveness studies in the ACCORD trial, *Am J Cardiol*, 2007; 99:S90-S102

# 120. Edlund MJ, Steffick D, Hudson T, Harris KM, **Sullivan MD** Risk Factors for Clinically recognized Opioid Abuse and Dependence Among Veterans Using Opioids for Chronic Non-Cancer Pain, *Pain,* 2007; 129:355-62.

121**. Sullivan MD**, Russo JE, Levy WC, Crane B, Spertus JA, Summary Health Status Measures in Advanced Heart Failure: association with clinical variables and outcome, *J Cardiac Failure,* 2007; 13:560-8.

122. Thielke SM, Fan MY, **Sullivan M**, Unutzer J, Pain limits the effectiveness of collaborative care for depression, *Am J Geriatr Psychiatry*. 2007; 15:699-707

123. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, **Sullivan MD**, Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol* 2007; 99:21i-33i.

124. Mozaffarian D, Anker SD, Anand I, Linker DT, **Sullivan MD**, Cleland JG, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC, Prediction of mode of death in heart failure: the Seattle Heart Failure Model. *Circulation* 2007; 116:392-8.

125. Moorman AJ, Mozaffarian D, Wilkinson CW, Lawler RL, McDonald GB, Crane BA, Spertus JA, Russo J, Stempien-Otero AS, **Sullivan MD**, Levy WC. In patients with heart failure elevated sTNFr1 is associated with higher risk of depression and/or antidepressant use *J Cardiac Failure* 2007; 13:738-43

126. Dougherty CM, Pyper G, Au DA, Levy WC, **Sullivan MD**, Drifting into a shrinking future: living and planning with advanced CHF. *J Cardiovasc Nurs*  2007; 22:480-487.

127. Edlund MJ, **Sullivan MD**, Steffick D, Harris K. Do users of prescribed opioids have higher rates of substance abuse problems than non-users? *Pain Med*  2007; 8:647-56.

128. Braden JB, Zhang L, Edlund MJ, Unutzer J, **Sullivan MD**, Mental health service use in older adults: the role of chronic pain.  *Am J Geriat Psychiatry* 2008; 16:156-167.

129. Ehde DM,Chwastiak L, **Sullivan MD,**Gibbons LE, Wadhwani R, Bombardier CH, Kraft GH, Efficacy of Paroxetine in treating major depressive disorder in persons with multiple sclerosis. *Gen Hosp Psychiatry* 2008; 30:40-8.

130. Ting HH, Bradley EH, Wang Y, Lichtman JH, Nallamothu BK, **Sullivan MD**, Gersh BJ, Roger VL, Curtis JP, Krumholz HM, Factors associated with longer time from symptom onset to hospital presentation for patients with ST-elevation myocardial infarction. *Arch Intern Med* 2008; 168:959-968.

131. Von Korff M, Saunders K, Ray GT, Boudreau D, Campbell C, Merrill J, **Sullivan MD,** Rutter C, Silverberg M, Banta-Green C, Weisner C. De facto long-term opioid therapy for non-cancer pain. *Clin J Pain* 2008; 24:521-7

132. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; 358:2545-59

133. **Sullivan MD,** Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC, Trends in use of opioids for non-cancer pain conditions in commercial and Medicaid insurance plans, 2000-2005: The TROUP Study. *Pain* 2008; 138:440–449

134. Dobscha SK, Corson K, Leibowitz RQ, **Sullivan MD**, Gerrity MS, Rationale, design and baseline findings from a randomized trial of collaborative care for chronic musculoskeletal pain in primary care. *Pain Med*  2008; 9:1050-64.

135. Hudson TH, Edlund MJ, Steffick D, **Sullivan MD**, Epidemiology of regular, prescribed opioid use: results from a national, population-based survey. *Pain Sympt Mgmt*  2008; 36:280-8.

136. Braden JB, Zimmerman F, **Sullivan MD,** Employment outcomes among individuals with mental health disorders and comorbid chronic pain. *Psychiatr Serv* 2008; 59:878-85.

137. Braden JB, Fan MY,Edlund MJ, Martin BC,DeVries A, **Sullivan MD** Trends in Use of opioids by non-cancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP Study. *J Pain*  2008; 9:1026-1035

# 138. **Sullivan MD**, Ciechanowski PS, Russo JE, Spertus JA, Soine LA, Jordan-Keith K, Caldwell JH, Angina pectoris during daily activities and exercise stress testing: the role of inducible myocardial ischemia and psychological distress, *Pain* 2008; 139:551–561

139. Braden JB, **Sullivan MD**, Suicidal thoughts and behavior among adults with self-reported pain Conditions in the National Comorbidity Survey Replication, *J Pain,* 2008; 9:1106-15.

140. **Sullivan MD**, Bentley S, Fan MY, Gardner G, A single-blind placebo run-in study of Duloxetine for activity-limiting osteoarthritis pain. *J Pain 2009*; 10:208-13

# 141. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, **Sullivan MD**, Marcovina SM, Launer LJ, The relationship between baseline glycemia and cognitive function in people with type 2 diabetes and other cardiovascular risk factors: the ACCORD - MIND Study. *Diabetes Care* 2009; 32:221-6.

# 142. Dobscha SK, Corson K, Perrin NA, Hanson GC, Leibowitz RQ, Doak MN, Dickinson KC, **Sullivan MD**, Gerrity MS. Collaborative care for chronic pain in primary care: a cluster-randomized trial. *JAMA* 2009; 301:1242-52

# 143. **Sullivan MD**, The quest for rational chronic pain pharmacotherapy, *Gen Hosp Psychiatry* 2009; 31:203-5.

# 144. Arnold SV, Spertus JA, Ciechanowski PC,Soine L, Jordan-Keith K, Caldwell JH, **Sullivan MD**, The psychosocial modulators of angina response to myocardial ischemia. *Circulation* 2009; 120:126-133

# 145. Weisner C, Campbell CI, Ray GT, Saunders K, Boudreau D, **Sullivan MD**, Merrill JO, Silverberg MJ, Banta-Green C, Von Korff M, Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. *Pain,* 2009; 145:287-93.

# 146. **Sullivan MD**, Ciechanowski PS, Russo JE, Soine LA, Jordan-Keith K, Caldwell JH, Understanding why patients delay seeking care for acute coronary syndromes, *Circulation Qual Outcomes* 2009; 2:148-154

147. Aggarwal SK, Carter GT, **Sullivan MD**, Morrill R, ZumBrunnen C, Mayer JD, Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. *J Opioid Mgmt* 2009; :153-168

# 148. Wohlreich MM, **Sullivan MD**, Mallinckrodt CH, Chappell AS, Myers TM, Watkin JG, Raskin J. Duloxetine for the treatment of major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis. *Psychosomatics* 2009; 50:402-412.

# 149. Boudreau D Von Korff M, Rutter C, Saunders K, Ray GT, **Sullivan MD**, Campbell CI, Merrill JO, Silverberg MJ, Banta-Green C, Weisner C. Trends in long-term opioid therapy for non-cancer pain. *Pharmacoepidemiol Drug Safety* 2009; 18:1166-75.

# 150. Braden JB, **Sullivan MD**, Ray GT, Saunders K, Merrill JO, Silverberg MJ, Rutter C, Weisner C, Banta-Green C, Campbell CI, Von Korff M. Trends in prescribed opioid therapy for non-cancer pain for persons with a history of depression. *Gen Hosp Psychiatry* 2009; 31:567-570

# 151. Aggarwal SK, Carter GT, **Sullivan MD**, ZumBrunnen C, Morrill R, Mayer JD.Chacteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. *J Opioid Manag,*  2009; 5:257-86.

# 152. **Sullivan MD**, Bentley S, Fan MY, Gardner G. A single-blind placebo run-in study of Venlafaxine for activity-limiting osteoarthritis pain. *Pain Med* 2009;10:806-12.

153. Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC **Sullivan MD.** Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP study. *Clin J Pain* 2010; 26:1-8.

154. Thielke S, Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC **Sullivan MD.**  Age and sex trends in long-term opioid use in two large American Health systems between 2000 and 2005. *Pain Med* 2010; 11:248-56.

155. Saunders KD, Dunn KM, Merrill JO, Weisner CM, Rutter CM, Braden JB, **Sullivan MD**, Psaty BM, Von Korff M. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med*  2010; 25:310-5156.

156. Dunn KM, Saunders KD, Rutter CM, Banta-Green CJ, Merrill JO, **Sullivan MD**, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Overdose and prescribed opioids: associations among chronic non-cancer pain patients. *Ann Intern Med* 2010; 152:85-92.

157. ACCORD Study Group, Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus, *N Engl J Med,* 2010; 362:1563-74

158. ACCORD Study Group, Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus,

*N Engl J Med,* 2010; 362:1575-85

159. **Sullivan MD**, Von Korff M, Banta-Green CJ, Merrill JO, Saunders KD Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain, *Pain,* 2010; 149:345-53

160. **Sullivan MD**, Gaster B, Russo JE, Bowlby L, Rocco N, Sinex N, Livovich J, Jasti H, Arnold RM, Randomized Trial of Web-based Training about Opioid Therapy for Chronic Pain, *Clin J Pain,* 2010; 26:512-7.

161. Banta-Green CJ, Von Korff M, **Sullivan MD**, Merrill JO, Doyle SR, Saunders KD,The Prescribed Opioids Difficulties Scale: A Patient-Centered Assessment of Problems and Concerns**,** *Clin J Pain,* 2010; 26:489-97.

162*.* **Sullivan MD,** Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC**,** Risks for Possible and Probable Opioid Misuse Among Recipients of Chronic Opioid Therapy in Commercial and Medicaid Insurance Plans: the TROUP Study, *Pain,* 2010; 150:332-339.

163. Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC **Sullivan MD,** An analysis of heavy utilizers of opioids for chronic non-cancer pain in the TROUP Study. J *Pain Sympt Mgmt,* 2010, 40:279-89

164. Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC **Sullivan MD,** Risks for Opioid Abuse and Dependence Among Recipients of Chronic Opioid Therapy: Results from the TROUP Study, *Drug and Alcohol Dependence,* 2010; 112:90-8.

165. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop‑Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet*. 2010; 376:419-30.

166. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD,

Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010; 363:233-44

167. Campbell CI, Weisner C, LeResche L, Ray GT, Saunders K, **Sullivan MD**, Merrill JO, Banta-Green C, Silverberg MJ, Boudreau D, Satre DD, Von Korff M. Age and sex trends in long-term opioid analgesic use for non-cancer pain. *Am J Public Health,* 2010; 100:2541-7

168. Braden JB, Russo JE, Fan MY,Edlund MJ, Martin BC,DeVries A, **Sullivan MD,** Emergency Department visits among recipients of chronic opioid therapy**.**  *Arch Intern Med,* 2010; 170:1425-1432

169. Ting HH, Chen AY, Roe MT, Chan PS, Spertus JA, Nallamothu BK, **Sullivan MD**, DeLong ER, Bradley EH, Krumholz HM, Peterson ED, Delay from Symptom Onset to Hospital Presentation for Patients with Non-ST-Elevation Myocardial Infarction, *Arch Intern Med* ; 170:1834-41.

170.Légaré F, Bekker H, Desroches S, Politi M, Stacey D, Borduas F, Cheater FM, Cornuz J, Coutu MF, Donner-Banzhoff N, Ferdjaoui-Moumjid N, Griffiths F, Härter M, Jackson C, Jacques A, Krones T, Labrecque M, Rodriguez R, Rousseau M, **Sullivan M**. Effective continuing professional development for translating shared decision making in primary care: A study protocol. Implement Sci. 2010 Oct 27;5:83. 6:

171. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet*. 2010 Aug 7;376(9739):419-30.

172. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD,
Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH,
Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U,
Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010; 363:233-44.

171. **Sullivan MD,** Who gets high-dose opioid therapy for chronic non-cancer pain?, *Pain,* 2010; 151:567-8.

172. Von Korff M, Merrill JO, Rutter CM, **Sullivan MD**, Campbell CI, Weisner CM, Time-Scheduled versus Pain-Contingent Opioid Dosing in Chronic Opioid Therapy, *Pain*, 2011 Jun; 152:1256-62.

173. **Sullivan MD**, Leach A, Looking beyond myocardial ischemia in chest pain treatment, *Pain*, 2011; 152:707-8

174. **Sullivan MD,** How Should We Limit the Potential Harms of High-Dose Opioid Therapy?, *Arch Int Med,* 2011, 171:691-692

175. Imes C, Dougherty C, **Sullivan MD**, A Descriptive Study Of Partner’s Experiences Of Living With Severe Heart Failure, *Heart/Lung,* 2011; 40:208-16.

176. Anderson RT, Feeney P, Narayan KMV, Goff DC, Ali MK, Simmons D, Bigger T, Cuddihy R, O’Connor PJ, Sperl-Hillen J, Sood A, Zhang P, Fine L, **Sullivan MD** Effect of Intensive Glycemic Lowering on Health-related Quality of Life in Type 2 Diabetes Mellitus : ACCORD Trial, *Diabetes Care,* 2011; 34:807-812.

177. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med*. 2011; 364:818-28.

178. Légaré F, Bekker H, Desroches S, Drolet R, Politi M, Stacey D, Borduas F, Cheater FM, Cornuz J, Coutu MF, Ferdjaoui-Moumjid N, Griffiths F, Härter M, Jacques A, Krones T, Labrecque M, Neely C, Rodriguez C, Sargeant J, Schuerman J, **Sullivan MD**, How can continuing professional development better promote shared decision-making? Perspectives from an international collaboration, *Implement Sci.* 2011; 6:68.

179. Martin BC,Fan MY, Edlund MJ, DeVries A, Braden JB, **Sullivan MD,** Long Term Chronic Opioid Therapy Discontinuation Rates From The TROUP Study, *J Gen* *Intern Med,* 2011; 26:1450-7.

180.Richardson LP, Fan MY, McCarty CA, Katon W, Edlund ME, DeVries A, Martin BC, **Sullivan MD**, Trends in the Prescription of Opioids for Adolescents with Non-cancer Pain, *Gen Hosp Psychiatry,* 2011; 33:423-8.

181. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, **Sullivan MD**, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O’Connor P, Lipkin EW, Hirsh J, Coker L, Maldjian J, Sunshine JL, Truit C, Davatzikos C, Bryan RN for ACCORD MIND Investigators, Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study, *Lancet Neurology*, 2011;10:969-77

182. Silverberg MJ, Ray GT, Saunders K, Rutter CM, Campbell CI, Merrill JO, **Sullivan MD**, Banta-Green C, Von Korff M, Weisner C, Prescription long-term opioid use in HIV-infected patients, *Clin J Pain,* 2012; 28:39-46

183. Braden JB, Young A, **Sullivan MD**, Walitt B, LaCroix AZ, Martin L, Predictors of Change in Pain and Physical Functioning among Post-Menopausal Women with Recurrent Pain Conditions in the Women’s Health Initiative Observational Cohort, *J Pain,* 2012,13:64-72

184. Aggarwal SK, Carter GT, Zumbrunnen C, Morrill R, **Sullivan M**, Mayer JD, Psychoactive substances and the political ecology of mental distress, *Harm Reduction Journal,* 2012, 9:4

185. Ali MK, Feeney P, Hire D, Simmons DL, O’Connor PJ, Ganz-Lord F, Goff D, Zhang P, Anderson RT, Narayan KMV, **Sullivan MD**, Glycemia and correlates of patient-reported outcomes in ACCORD trial participants, *Diabetic Medicine,* 2012; 29:e67-e74.

186. Franklin GM, Mai J, Turner J, **Sullivan M**, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: Impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012; 55:325-31.

187. Saunders K, Von Korff M, Campbell CI, Banta-Green CJ, **Sullivan MD**, Merrill JO, Weisner C, Concurrent Use of Alcohol and Sedatives among Persons Prescribed Chronic Opioid Therapy: Prevalence and Risk Factors, *J Pain,* 2012; 13:266-75

188. Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman-Yaffee T, Seaquist ER, Ismail-Beigi F, **Sullivan MD**, Lovato LC, Bergenstal RM, Gerstein HC, Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial, *Diabetes Care,* 2012; 35:787-793

189. **Sullivan MD**, Ballantyne JC, What are we treating with long-term opioid therapy?, *Arch Int Med* 2012; 172:433-4.

190. Richardson LP, Russo JE, McCarty CA, Katon W, Edlund ME, DeVries A, Martin BC, **Sullivan MD** Mental health disorders and chronic opioid use among adolescents and young adults with chronic pain, *J Adol Health* 2012; 50:553-8.

191. **Sullivan MD,** O’Connor PJ, Feeney P, Hire D, Simmons D, Raisch D, Fine L, Narayan KMV, Ali MK, Katon W, Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy, *Diabetes Care,* 2012, 35:1708-15

192. O’Connor PJ, Narayan KM, Anderson RT, Feeney P, Fine L, Ali MK, Simmons DL, Hire DG, Sperl-Hillen JM, Katz LA, Margolis KL, **Sullivan MD**, Effect of Intensive versus Standard Blood Pressure Control on Depression and Health-Related Quality of Life in Type 2 Diabetes Mellitus: ACCORD Trial, *Diabetes Care,* 2012; 35:1479-81.

193. Raisch DW, Feeney P, Goff DC, Narayan KM, O'Connor PJ, Zhang P, Hire DG, **Sullivan MD**,
Baseline Comparison of Three Health Utility Measures and the Feeling Thermometer among Participants in the Action to Control Cardiovascular Risk in Diabetes Trial, *Cardiovascular Diabetology,*  2012 Jul 11;11:35.

194. Howe CQ, **Sullivan MD**, Saunders KW, Merrill JO, Banta-Green CJ, Weisner C, Campbell CI, Von Korff M, Depression and Ambivalence toward Chronic Opioid Therapy for Chronic Non-cancer Pain, *Clin J Pain,* 2012; 28:561-6.

195. Grattan A, **Sullivan MD**, Saunders KW, Campbell CI, Von Korff M, The Association of Depression and Self-reported Prescription Opioid Misuse Among Recipients of Chronic Opioid Therapy
Without a History of Substance Abuse, *Ann Fam Med,* 2012; 10:304-11.

196. **Sullivan MD**, Evans G, Anderson RT, O’Connor P, Raisch DW, Simmons DL, Narayan KM, Diabetes Symptoms and Distress in ACCORD Trial Participants: Relationship to Baseline Clinical Variables, *Current Diabetes,* 2012; 30:101-109

197. Aggarwal SK, Carter GT, Zumbrunnen C, Morrill R, **Sullivan M**, Mayer JD, Psychoactive substances and the political ecology of mental distress. Harm Reduct J. 2012; 9:4.

198. Aggarwal SK, Carter GT, **Sullivan MD**, ZumBrunnen C, Morrill R, Mayer JD, Prospectively Surveying Health-Related Quality of Life and Symptom Relief in a Lot-Based Sample of Medical Cannabis-Using Patients in Urban Washington State Reveals Managed Chronic Illness and Debility, *Am J Hosp Palliat Care* 2013; 30:523-31. doi: 10.1177/1049909112454215. PubMed PMID:22887696.

199. Ballantyne JC, **Sullivan MD**, Kolodny A, Opioid dependence versus addiction: a distinction without a difference?, *Arch Intern Med*, 2012; 13:1-2.

200. Merrill JO, Korff MV, Banta-Green CJ, **Sullivan MD**, Saunders KW, Campbell CI, Weisner C. Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients. *Gen Hosp Psychiatry*. 2012; 34:581-7

201. Ballantyne JC**, Sullivan MD**, Why Doctors Prescribe Opioids to Known Opioid Abusers, *New Engl J Med,* 2013; 368:484-485

202. Bombardier CH, Ehde DM, Gibbons LE, Wadhwani R, **Sullivan MD**, Rosenberg D, Kraft GH, Telephone-based Physical Activity Counseling for Major Depression in People with Multiple Sclerosis, *J Consult Clin Psychol,* 2013; 81:89-99.

203. Roy-Byrne P, **Sullivan MD**, Sherbourne CD, Golinelli D, Craske MG, Sullivan G, Stein MB, Effects of Pain and Prescription Opioid Use on Outcomes in a Collaborative Care Intervention for Anxiety, *Clin J Pain,* 2013; 29:800-6. doi: 10.1097/AJP.0b013e318278d475.

204. Krashin D, **Sullivan M**, Ballantyne J. What are we treating with chronic opioid therapy? *Curr Rheumatol Rep*. 2013; 15:311.

205. Aggarwal SK, Carter GT, **Sullivan MD,** Morrill R, ZumBrunnen C, Mayer JD.  Distress, Coping, and Drug Law Enforcement in a Series of Medical Cannabis Patients. *J Nerv Ment Dis* 2013; 201:292-303

206. \***Sullivan MD**, Cahana A, Derbyshire SW, Loeser JD, What does it mean to call chronic pain a brain disease?, *J Pain*; 2013; 14:317-22.

207. **Sullivan MD**, Cahana A, Derbyshire S, Loeser JD. Reply to commentaries. *J Pain;* 2013; 14:336-7

208. Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. *Diabetes Care*. 2013 Aug;36(8):2162-8. doi: 10.2337/dc12-1391.

209. Rumsfeld JS, Alexander KP, Goff DC Jr, Graham MM, Ho PM, Masoudi FA, Moser DK, Roger VL, Slaughter MS, Smolderen KG, Spertus JA, **Sullivan MD**, Treat-Jacobson D, Zerwic JJ; Cardiovascular Health: The Importance of Measuring Patient-Reported Health Status: A Scientific Statement From the American Heart Association. *Circulation,* 2013 May 6. [Epub ahead of print]

210. Ballantyne JC, **Sullivan MD**, Kolodny A. Dependence is not addiction and "tolerance" declares addiction-reply. *JAMA Intern Med*. 2013; 173:595-6.

212. Aggarwal SK, Carter GT, **Sullivan MD**, ZumBrunnen C, Morrill R, Mayer JD, From 32 Ounces to 0: A Medical Geographic Study of Dispensing a Cultivated Lot of “Plum” Cannabis Flowerbuds to Qualifying Medical Marijuana Patients in Washington State, *J Psychoactive Drugs,* 2013; 45:141-155

213. Franklin GM, Turner J, **Sullivan MD**, Wickizer T, Fulton-Kehoe D, Changes in opioid prescribing for chronic pain in Washington State, *J Am Board Fam Med,* 2013; 26:394–400

214*.* Edlund MJ, **Sullivan MD**, Han X, Booth BM, Days with Pain and Substance Use Disorders: Is There an Association?, *Clin J Pain*; 2013; 29:689-95.

215. Bekelman DB, Plomondon ME, **Sullivan MD**, Nelson K, Hattler B, McBryde C, Leymann K, Rumsfeld K, Patient-centered disease management (PCDM) for heart failure: study protocol for a randomised controlled trial, *BMC Cardiovascular Disorders*. 2013, 13:49,

216. **Sullivan MD**, Katon WJ, Lovato LC, Miller ME, Murray AM, Horowitz KR, Bryan RN, Gerstein HC, Marcovina S, Akpunonu BE, Johnson J, Yale JF, Williamson J, Launer LJ, Depression is associated with accelerated cognitive decline among patients with Type 2 diabetes in the ACCORD-MIND trial, *JAMAPsychiatry*, 2013; 70(10):1041-7.

217. **Sullivan MD,** Clarifying opioid misuse and abuse, *Pain,*  2013; 154(11):2239-40.

218. \***Sullivan MD,** Howe CI, Opioid Therapy for Chronic Pain in the US: promises and perils, *Pain,*  2013; 154 Suppl 1:S94-100.

219. Fulton-Kehoe D, Garg RK, Turner J, Bauer A, Wickizer T, **Sullivan MD**, Franklin GM, Opioid Poisonings and Opioid Adverse Effects in Workers in Washington State, *Am J Ind Med,*  2013; 56(12):1452-62. doi: 10.1002/ajim.22266.

220. Howe CQ, **Sullivan MD**, The Missing 'P' in Pain Management: How the Current Opioid Epidemic Highlights the Need for Psychiatric Services in Chronic Pain Care, *Gen Hosp Psychiatry,* 2014; 36:99-104. doi: 10.1016/j.genhosppsych.2013.10.003.

221. Garg RK, Fulton-Kehoe D, Turner J, Bauer A, Wickizer T, **Sullivan MD**, Franklin GM, Changes in Opioid Prescribing for Washington Workers’ Compensation Claimants after Implementation of an Opioid Dosing Guideline for Chronic Non-Cancer Pain: 2004-2010, *J Pain,* 2013 Dec;14(12):1620-8. doi: 10.1016/j.jpain.2013.08.001.

222. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, **Sullivan MD**, Horowitz KR, Ding J, Marcovina S, Lovato L, Lovato J, Margolis KL, Davatzikos C, Barzilay J, Ginsberg HN, Linz PE, Miller ME; for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Memory in Diabetes (MIND) Investigators. Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels: A Randomized Clinical Trial. *JAMA Intern Med*. 2014; 174:324-333. doi:10.1001/jamainternmed.2013.13656

223. **Sullivan MD**, Will data destroy our faith in long-acting opioids?, *Pain,* 2014; 155:843-4. doi: 10.1016/j.pain.2014.01.032.

224. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014 Jul;30(7):557-64.

 doi: 10.1097/AJP.0000000000000021. PubMed PMID: 24281273; PubMed Central PMCID: PMC4032801.

225. Fillingim RB, Bruehl S, Dworkin RH, Dworkin SF, Loeser JD, Turk DC, Widerstrom-Noga E, Arnold L, Bennett R, Edwards RR, Freeman R, Gewandter J, Hertz S, Hochberg M, Krane E, Mantyh PW, Markman J, Neogi T, Ohrbach R, Paice J, Porreca F, Rappaport BA, Smith SM, Smith TJ, **Sullivan MD**, Verne GN, Wasan AD, Wesselmann U, The ACTTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multi-Dimensional Approach to Classifying Chronic Pain Conditions, *J Pain,* 2014; 15:241-9. doi: 10.1016/j.jpain.2014.01.004.

226.Edlund MJ, Austen MA, **Sullivan MD**, Martin BC, Williams JS, Fortney JC, Hudson TJ, Patterns of Opioid Use for Chronic Non-Cancer Pain in the Veterans Health Administration from 2009 to 2011, *Pain*, 2014; 155:2337-43. doi: 10.1016/j.pain.2014.08.033.

227.Vanderlip E, **Sullivan MD**, Edlund MJ, Martin BC, Fortney J, Austen M, Williams JS, Hudson TJ, National Study of Discontinuation of Long-Term Opioid Therapy among Veterans, *Pain,* 2014; 155:2673-9. doi: 10.1016/j.pain.2014.09.034.

228. Gereau RW, Sluka KA, Maixner W, Savage SR, Price TJ, Murinson BB, **Sullivan MD**, Fillingim RB, A Pain Research Agenda for the 21st Century, *J Pain,* 2014 Dec;15(12):1203-14. doi: 10.1016/j.jpain.2014.09.004.

229. Bekelman DB, Plomondon ME, Carey EP, **Sullivan MD**, Nelson KM, Hattler B, McBryde CF, Lehmann KG, Gianola K, Heidenreich PA, Rumsfeld JS, Primary Results of the Patient-Centered Disease Management (PCDM) for Heart Failure Study: A Randomized Clinical Trial, *JAMA Intern Med*.  2015 May 1;175(5):725-32. doi: 10.1001/jamainternmed.2015.0315.

230. Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC; Look AHEAD Research Group; ACCORD Study Group. Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. Am J Hypertens. 2015 Aug;28(8):995-1009. doi: 10.1093/ajh/hpu292. Epub 2015 Feb 9. PubMed PMID: 25666468; PubMed Central PMCID: PMC4506323.

231. Howe CQ, Robinson JP, **Sullivan MD**. Psychiatric and Psychological Perspectives on Chronic Pain. *Phys Med Rehabil Clin N Am*. 2015; 26:283-300. doi: 10.1016/j.pmr.2014.12.003. PubMed PMID: 25952065.

232. Fulton-Kehoe D, Garg RK, Turner J, Bauer A, Wickizer T, **Sullivan MD**, Franklin GM, Opioid Poisonings in Washington State Medicaid: Trends, Dosing, and Guidelines, *Medical Care* 2015;53: 679–685, PMID: 26172937

233. **Sullivan MD**, What are we treating with opioid and sedative-hypnotic combination therapy?, *Pharmacoepidemiology and Drug Safety,* 2015; 24:893-5. doi: 10.1002/pds.3821, PMID: 26098538

234. **Sullivan MD,** Derbyshire SWG, Is there a purely biological core to pain experience?, *Pain,* 2015; 156:2119-20. doi: 10.1097/j.pain.0000000000000357. PMID: 26371796

235. **\*Sullivan MD,** Ballantyne J, Must we reduce pain intensity to treat chronic pain?, *Pain,* 2016; 157:65-9. doi: 10.1097/j.pain.0000000000000336. PMID: 26307855 [Top 25 Cited Articles in *Pain* in 2016]

236. Ballantyne J, **Sullivan MD,** Intensity of chronic pain: wrong metric?, *New Engl J Med,* 2015, 373:2098-99, PMID: 26605926

237. Scherrer JF, Salas J, Copeland LA, Stock EM, Schneider FD, **Sullivan MD**, Bucholz KK, Burroughs T, Lustman PJ, Prescription Opioid Duration, not Dose, is Associated with Increased Risk of Depression in Three Large Patient Populations, *Ann Fam Med,* 2016; 14:54-62. doi: 10.1370/afm.1885. PMID: 26755784

238. **Sullivan MD**, Fulton-Kehoe D, Garg RK, Turner J, Bauer A, Wickizer T, Franklin GM, Trends in Opioid Dosing Among of Washington State Medicaid Patients Before and After Opioid Dosing Guideline Implementation, *J Pain,* 2016 May;17(5):561-8. doi: 10.1016/j.jpain.2015.12.018. Epub 2016 Jan 30. PMID: 26828802

239. Scherrer JF, Salas J, Copeland LA, Stock EM, Schneider FD, **Sullivan MD**, Bucholz KK, Burroughs T, Lustman PJ, Risk of depression associated with codeine, hydrocodone or oxycodone, *Pharmacoepidemiology and Drug Safety,*2016 May;25(5):560-8. doi: 10.1002/pds.3999. Epub 2016 Mar 22. PMID: 27004714

240. Scherrer JF, Salas J, **Sullivan MD**, Schneider FD, Bucholz KK, Burroughs T, Copeland L, Ahmedani B, Lustman PJ, The Influence of Prescription Opioid Use Duration and Dose on Development of Treatment Resistant Depression, *Preventive Medicine,* 2016; 91:110-116. doi: 10.1016/j.ypmed.2016.08.003. PMID: 27497660

241. **Sullivan MD,** Why does depression promote long-term opioid use?, *Pain*. 2016, 157:2395-6

 PMID: 27385503

242. Edwards RR, Dworkin RH, **Sullivan MD**, Turk D, Wasan AD, The role of psychosocial processes in the development and maintenance of chronic pain disorders, *J Pain*, (Suppl. 2) 2016, 17:T70-T92 PMID: 27586832

243. Murray AM, Hsu FC, Williamson JD, Bryan RN, Gerzstein HC, **Sullivan MD**, Miller ME, Leng I, Lovato LL, Launer LJ, ACCORDION MIND: Results of the observational extension study of ACCORD MIND randomized trial, *Diabetologia,* 2017; 60:69-80. PMID:27766347

244. Graham HT, Rotroff DM, Marvel SW, Buse JB, Havener TM, Wilson AG, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.. Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. *Front Genet*. 2016; 7:138. PMID: 27775101.

245. **\*Sullivan MD**, Turner JA, DiLodovico C, D’Appolonio A, Stephens KA, Chan YF, Prescription Opioid Taper Support for Outpatients with Chronic Pain: A Randomized Controlled Trial, *J Pain,* 2017; 18:308-318. doi: 10.1016/j.jpain.2016.11.003.  PMID: 27908840

246. Krashin D, Murinova N, Sullivan M, Challenges to Treatment of Chronic Pain and Addiction During the “Opioid Crisis”, *Current Pain and Headache Reports*, 2016; 20:65.PMID: 27873121

247. Scherrer JF, Salas J, Schneider FD, Bucholz KK, **Sullivan MD**, Copeland LA, Stock EM, Ahmedani B, Burroughs T, Lustman PJ, Characteristics of New Depression Diagnoses in Patients with and without Prior Chronic Opioid Use , *J Affective Dis,* 2017; 210:125-129. PMID: 28033519

248. Salas J, Scherrer JF, Schneider FD, **Sullivan MD**, Buchohlz KK, Burroughs T, Copeland LA, Ahmedani BK, Lustman PJ, New Onset Depression Following Stable, Slow and Rapid Rate of Prescription Opioid Dose Escalation, *Pain,* 2017; 158:306–312. PMID: 28092649

249.Braden JK, Edlund MJ, **Sullivan MD,** Trends in Suicides with Opioids Listed as a Contributing Cause of Death in the United States, 1999-2014, *American Journal of Public Health,*  2017; 107:421-426. PMID: 28103068

250. Hudson T, Painter JT, Austen MA, Williams JS, Fortney JC, **Sullivan MD**, Edlund ME, Pharmacoepidemiologic Analyses of Opioid Use among OEF/OIF/OND Veterans, *Pain,* 2017; 158:1039-1045. doi: 10.1097/j.pain.0000000000000874. PMID: 28195856

251. **Sullivan MD**, Vowles KE. Patient action: as means and end for chronic pain care. *Pain.* 2017; 158:1405-1407. doi: 10.1097/j.pain.0000000000000921. PMID: 28426549 [Top 25 accessed articles in 2017 in Pain]

252. Freedman BI, Sink KM, Hugenschmidt CE, Hughes TM, Williamson JD, Whitlow CT, Palmer ND, Miller ME, Lovato LC, Xu J, Smith SC, Launer LJ, Barzilay JI, Cohen RM, **Sullivan MD**, Bryan RN, Wagner BC, Bowden DW, Maldjian JA, Divers J, Associations between early kidney disease with brain MRI and cognitive function in African Americans with type 2 diabetes, *Am J Kidney Dis.* 2017; 70:627-637. doi: 10.1053/j.ajkd.2017.05.006. Epub 2017 Jun 23.PMID:28648301

253. Ballantyne JC, **Sullivan MD,** The discovery of endogenous opioid systems: what it has meant for the clinician’s understanding of pain and its treatment, *Pain,* 2017; 158:2290-2300. doi: 10.1097/j.pain.0000000000001043. PMID: 28832397

254. Ehde DM, Alschuler KN, **Sullivan MD**, Molton IP, Ciol MA, Bombardier CH, Curran MC, Gertz KJ, Wundes A, Fann JR, Improving the quality of depression and pain care in multiple sclerosis using collaborative care: The MS-Care trial protocol. *Contemporary Clinical Trials*, 2017, Oct 5. pii: S1551-7144(17)30330-0. doi: 10.1016/j.cct.2017.10.001. [Epub ahead of print] PMID:28987615

255. Singh K, Kondal D, Shivashankar R, Ali MK, Pradeepa R, Ajay VS, Mohan V,Kadir MM, **Sullivan MD**, Tandon N, Narayan KM, Prabhakaran D, Health-related quality of life variations by sociodemographic factors and chronic conditions in three metropolitan cities of South Asia: the CARRS study, *BMC Open,*Oct 15;7(10):e018424. doi: 10.1136/bmjopen-2017-018424. PMID: 29038187

256. Hooten WM, Brummett CM, **Sullivan MD**, Goesling J, Tilburt JC, Merlin JS, St. Sauver JL, Wasan AD, Clauw DJ, Warner DO, A Conceptual Framework for Understanding Unintended Prolonged Opioid Use, *Mayo Clin Proc,* 2017; 92:1822-1830. doi: 10.1016/j.mayocp.2017.10.010. Epub 2017 Nov 3. PMID: 29108841

257. Hudson TJ, Painter JT, Gressler LE, Lu L, Williams JS, Booth BM, Martin BC, **Sullivan MD**, Edlund MJ. Factors Associated with Opioid Initiation in OEF/OIF/OND Veterans with Traumatic Brain Injury. Pain Med. 2017 Sep 26. doi:10.1093/pm/pnx208. [Epub ahead of print] PubMed PMID: 29036680.

258. Salas J, Scherrer JF, Ahmedani BK, Copeland LA, Bucholz KK, **Sullivan MD**, Burroughs T, Schneider FD, Lustman PJ. Gender and the Association between Long-Term Prescription Opioid Use and New-Onset Depression. J Pain. 2018; 19:88-98. doi: 10.1016/j.jpain.2017.09.004. PMID: 29030323.

259.Langford DJ, Theodore BR, Balsiger D, Tran C, Doorenbos AZ, Tauben D, **Sullivan MD**, Number and Type of Post-Traumatic Stress Disorder (PTSD) Symptom Domains is associated with Patient-Reported Outcomes in Patients with Chronic Pain, *J Pain,* 2018; 19:506-514. doi: 10.1016/j.jpain.2017.12.262.

260. **Sullivan MD,** New Opioid Policy: are we throwing out the baby with the bathwater?, *Pain Medicine,* 2018; 19:808-812. doi: 10.1093/pm/pnx330. PMID:29304255

261. **Sullivan MD,** Dangerously Numb: opioids, benzodiazepines, chronic pain and PTSD, *Pain,* 2018; 159:407-408. doi:10.1097/j.pain.0000000000001128. PubMed PMID: 29334531.

262. Scherrer JF, Salas J, Copeland LA, Stock EM, Schneider FD, **Sullivan MD**, Bucholz KK, Burroughs T, Lustman PJ, Impact of adherence on long-term prescription use cessation, *Br J Psychiatry,* 2018; 212(2):103-111. doi: 10.1192/bjp.2017.25. PMID: 29436331

263. Langford DJ, Tauben D, Sturgeon JA, Godfrey DS, **Sullivan MD**, Doorenbos AZ, Treat the Patient, Not the Pain: using a Multidimensional Patient-Reported Outcomes Tool to Facilitate Comprehensive Patient-Centered Chronic Pain Care, *J Gen Int Med,* 2018; 33:1235-1238. doi: 10.1007/s11606-018-4456-0 PMID:29717411

264. Vowles KE, Witkiewitz K, Pielech M, Edwards KA, McEntee ML, Bailey RW, Bolling LA, **Sullivan MD**. Alcohol and opioid use in chronic pain: A cross-sectional examination of differences in functioning based on misuse status. *JPain.* 2018;  *19:*1091-1230*.*doi: 10.1016/j.jpain.2018.04.013. PMID: 29758355

265. **Sullivan MD,** Depression effects on long-term opioid use, abuse and addiction, *Clin J Pain,* 2018 Sep;34(9):878-884. doi: 10.1097/AJP.0000000000000603.] PMID:29505419

266. Mazereeuw G, **Sullivan MD**, Juurlink DN. Depression in Chronic Pain: Might Opioids Be Responsible? Pain. 2018 Nov;159(11):2142-2145. doi: 10.1097/j.pain.0000000000001305. PMID: 29905651

267. **Sullivan M**, Langford DJ, Davies PS, Tran C, Vilardaga R, Cheung G, Yoo D, McReynolds J, Lober WB, Tauben D, Vowles KE, A controlled pilot trial of PainTracker Self-Manager, a web-based platform combined with patient coaching, to support patients’ self-management of chronic pain**,** *J Pain,* 2018 Sep;19(9):996-1005. doi: 10.1016/j.jpain.2018.03.009. PMID:29605691

268. Darnall BD, **Sullivan MD**, On the importance of using the right metrics for patient outcomes and payment: pain, pain interference, and physical function, *Pain Medicine,* 2018; Sep 21. doi: 10.1093/pm/pny147. [Epub ahead of print]

269. Lo SY, Winston-McPherson GN, Starosta AJ, **Sullivan MD**, Baird GS, Hoofnagle AN, Greene DN, Cannabis legalization does not influence patient compliance with opioid therapy, *Am J Med* 2018 pii: S0002-9343(18)31047-7. doi: 10.1016/j.amjmed.2018.11.002

270.Patel KV, Guralnik JM, Phelan EA, Gell NM, Wallace RB, **Sullivan MD**, Turk DC, Symptom Burden among Community-Dwelling Older Adults in the United States, *J Am Geriat Soc***,**  2019; 67:223-231. doi: 10.1111/jgs.15673. PMID:30548453

271. **Sullivan MD**, Clarifying our cultural contest about chronic pain, *Pain,* 160 (2019) 160(2):279-280. doi: 10.1097/j.pain.0000000000001455.PMID:30673685

272. **Sullivan MD**, What do we owe to patients with chronic pain?, *Pain Medicine,* 2019 May 1;20(5):878-881. doi: 10.1093/pm/pny219. PMID:30649544

273. Kroenke K, Alford DP, Argoff C, Canlas B, Covington E, Frank JW, Haake KJ, Hanling S, Hooten WM, Kertesz SG, Kravitz RL, Krebs EE, Stanos SP Jr, **Sullivan M**. Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report. Pain Med. 2019 Apr 1;20(4):724-735. doi: 10.1093/pm/pny307.PMID: 30690556.

In press

1. Scherrer JF, Salas J, Copeland LA, Stock EM, Schneider FD, **Sullivan MD**, Bucholz KK, Burroughs T, Lustman PJ, Increased Risk of Depression Recurrence after Initiation of Prescription Opioids in Non-Cancer Pain Patients, *J Pain*
2. Ballantyne JC, **Sullivan MD,** Koob GF, Refractory Dependence on Opioid Analgesics, *Pain*

# Book Chapters

1. Dobie RA, Katon WJ, **Sullivan M**, Sakai C: Tinnitus, depression, and aging. In: Goldstein JC, Kashima HK, Koopman CF (eds.). Geriatric Otorhinolaryngology*.*  Philadelphia: B. C. Decker Co., 1989.

2. **Sullivan MD**, Katon WJ, Roy-Byrne PR: The treatment of anxiety in primary care. In: Roth M, Burrows GD (eds.).Handbook of Anxiety*,* Vol. 4. Amsterdam: Elsevier Science Publishers, 1990.

3. **Sullivan MD**, Tucker GJ: The future of psychiatric research: The need for a conceptual agenda. In: Hsu LKG, Hersen M (eds.). Research in Psychiatry: Issues, Strategies, and Methods. Plenum, 1992.

4. Dobie RA, **Sullivan MD**: Antidepressants and tinnitus. In: Vernon J (ed.). Tinnitus. Plenum, 1994.

5. Katon W, **Sullivan M**, Clark MR: Cardiovascular disorders. In: Saddock BJ and Kaplan HI (eds.). Textbook of Psychiatry. Baltimore, Philadelphia: Williams & Wilkins, 1995, pp. 1491-1500.

6. Katon WJ, **Sullivan MD**: Antidepressant treatment of somatic symptoms. In: Mayou R, Bass C, Sharpe M, (eds.). Treatment of Functional Somatic Symptoms. Oxford: Oxford University Press, 1995, pp. 103-121.

7. **Sullivan MD**: Mental health therapies. In: Reich W (ed.). Encyclopedia of Bioethics. New York: MacMillan Co., 1995, pp. 1724-1730.

8. **Sullivan MD**: Diagnosis and treatment of pain disorder. In: Dunner DL (ed). Current PsychiatricTherapy II.Philadelphia, PA: W.B. Saunders Co., 1997, pp. 353-358.

9. Dobie RA, **Sullivan MD**: Antidepressant drugs and tinnitus. In: Vernon J (ed.). Treatment of Tinnitus. Prentice Hall, 1997.

10. **Sullivan MD**: Depression and the refusal of life-saving treatment. In: Steinberg M, Youngner S. (eds). End of Life Decisions: A Psychosocial Perspective*.* American Psychiatric Press, 1998.

11. **Sullivan MD**: Between first-person and third-person perspectives on pain. In: Devor M, Rowbotham M, Wiesenfeld-Hallin (eds). Proceedings of the Ninth World Congress on Pain. Seattle: IASP Press, 2000.

12. **Sullivan MD**, Turk DC: Psychiatric disorders and psychogenic pain. In: Loeser J. D., Butler S, Turk DC (eds). Bonica’s Management of Pain, 3rd Ed. Williams and Wilkins, 2000, pp. 483-500.

13. **Sullivan MD**: Pain disorders. In: Glen Gabbard (ed). Treatments of Psychiatric Disorders, 3rd Ed. Am Psychiatric Press, 2000, pp.1777-1800.

14. **Sullivan MD**: Assessment of psychiatric disorders. In: Turk D, Melzack R (eds). Handbook of Pain Assessment. 2nd Ed., Guilford Press, 2001, pp. 275-291.

15. **Sullivan MD,** What are the goals of pain treatment?, In: Dworkin RH, Breitbart WS. Psychosocial Aspects of Pain: A Handbook for Health Care Providers. Seattle: IASP Press, 2004

16. **Sullivan MD,** Pain, Psychiatry and Ethics, In: Schmidt RF, and Willis WD eds., *Encyclopedic Reference of Pain,* Heidelberg, Springer-Verlag, 2005

17. **Sullivan MD,** Ethics of Disability Evaluations, In: Schmidt RF, and Willis WD eds., *Encyclopedic Reference of Pain*, Heidelberg, Springer-Verlag, 2005

18. **Sullivan MD**: Mental Health Therapies. *Encyclopedia of Bioethics,* 3rd edition, Post, SG ed., 2004, New York: Macmillan Reference USA.

19. **Sullivan MD**, Zucker DS, Becoming Mindful of Pain Narratives, in Carr DB, Loeser JD, Morris DB, eds., Narrative, Pain and Suffering, Seattle, IASP Press, 2005, pp. 317-324

20. Bekelman D, **Sullivan MD**, Depression and Anxiety in Patients with Heart Failure, in Beattie JM, Goodlin SH, eds., *Palliative and Supportive Care in Heart Failure*, Oxford Univ. Press, 2008

21. Saxon AJ, **Sullivan MD,**  Robinson JP, Assessment and treatment of chemical dependency, in Chapman CR, Fishman S, eds., Bonica’s Management of Pain, 4th Ed. Williams and Wilkins, 2008

22. Wasan AD, **Sullivan MD,** Clark MR, Psychiatric Illness, Depression, Anxiety, and Somatoform Pain Disorders, Bonica’s Management of Pain, 4th Ed. Williams and Wilkins, 2008

23. Schellenberg I, **Sullivan MD**, Ethics and Pain Management, *Behavioral and Psychopharmacological Pain Management*, eds. Ebert M, Kerns R, Cambridge University Press, 2010

24. **Sullivan MD**: Mental health therapies. In: Jennings, B (ed.). *Bioethics, 4th Edition.* Edited by Bruce Jennings. Farmington Hills, MI: Macmillan Reference USA, 2014.

25. **Sullivan MD**, Psychogenic pain: old and new, *Routledge Handbook on the Philosophy of Pain,* ed. Jennifer Corns, London, Routledge, 2017

26. **Sullivan MD,** Ballantyne JC**,** “Is there a duty to relieve pain?”, in *Pain Neuroethics,* ed. Karen Davis, Cambridge MA, Elsevier (Academic Press), 2018

# Books

1. **Sullivan MD,** *Knowing and Healing: A Study of the Role of Self-Aware Activity in Medicine*, pp. 425. Dissertation awarded Ph.D. in Philosophy, Vanderbilt University, 1982, published by University Microfilms, Ann Arbor, MI.

2. Scheiber S, Abroms G, Culver C, Dubovsky S, Harrison S, Hawkins D, Lief H, Nadelson C, Robinowitz C, Werkman S, Zimmerman V, Gert B, Dillon J, Giray E, Hollander E, McKenna K, **Sullivan M**: *A Casebook in Psychiatric Ethics*. Group for the Advancement of Psychiatry. Washington, D.C.: American Psychiatric Association Press, Inc., 1990.

3. Katon W, Ludman E, Simon G, Lin E, **Sullivan M**, Walker E, Bush T, Von Korff M, Carter L: *Depression: Recurrent and Chronic*. New York, Time Life Medical, 1996.

4. \***Sullivan MD,** *The Patient As Agent of Health and Health Care*, New York, Oxford University Press, 2017

# Letters to the Editor

**Sullivan MD**: Panic disorder in patients with dizziness. *Arch Intern Med* 154:591, 1994.

**Sullivan MD**: Antidepressants and tinnitus. *Arch Intern Med* 154:1411, 1994.

**Sullivan MD**: Tinnitus vs. auditory hallucinations. *Arch Intern Med* 154:1921, 1994.

Ganzini, L, **Sullivan MD**: Patient requests for physician-assisted suicide. *JAMA* 281 (3):227-228, 1999.

**Sullivan MD,** Simon GR, Russo JE, Spertus JA: Depression and negative outcomes in heart failure. *Arch Intern Med* 163:498-499, 2003.

**Sullivan MD**, Leigh J, Gaster B, Response to Baca, *J Gen Intern Med*. 2006; 21:1129

Braden JB, **Sullivan MD,** Correcting Several Oversimplifications of Chronic Opioid Therapy—Reply, *Arch Intern Med,* 2011; 171:597-598*.*

**Sullivan MD**, Ballantyne JC, Clinician identification of long-term opioid candidacy- a reply *Arch Intern Med* 2012; 172:1110

Ballantyne JC, **Sullivan MD**. Intensity of Chronic Pain. N Engl J Med. 2016; 374:1395, doi: 10.1056/NEJMc1516797. PubMed PMID: 27050232.

ABSTRACTS/PRESENTATIONS

3-25-88 “Psychiatric Sources of Tinnitus Disability,” American Psychosomatic Society, 1988 Annual Meeting, Toronto, Canada.

4-22-88 “Treatment of Disabling Tinnitus with Tricyclic Antidepressants,” American Neuro-otology Society, 1988 Annual Meeting, Palm Beach, FL.

5-08-89 “Michel Foucault and the Truth of Madness,” American Psychiatric Association, 1989 Annual Meeting, San Francisco, CA.

5-10-89 “Depression and Tinnitus: Nortriptyline Treatment,” American Psychiatric Association, 1989 Annual Meeting, San Francisco, CA.

10-20-89 “Recognition of Psychological Influences on Chronic Pain Problems,” University of Washington CME, Seattle, WA.

10-27-89 “Chronic Tinnitus Treatment: A Model for the Treatment of Comorbidity,” Academy of Psychosomatic Medicine, 1989 Annual Meeting, Las Vegas, NV.

2-03-91 “Measurement of Tinnitus Severity,” Mid-Winter Research Meeting, Association for Research in Otolaryngology, St. Petersburg, FL.

5-10-91 “Treating and Rating Disability in a Pain Clinic,” Annual Meeting of Washington Labor and Industries Attorneys, North Bend, WA.

5-12-91 “On the Possibility of a Biological Psychopathology,” Annual Meeting of the Association for the Advancement of Philosophy and Psychiatry, New Orleans, LA.

5-14-91 “Ethics and the Perfection of Psychopharmacology,” American Psychiatric Association, 1991 Annual Meeting, New Orleans, LA.

5-16-91 “Depression Severity Predicts Medical Disability,” American Psychiatric Association, 1991 Annual Meeting, New Orleans, LA.

5-31-91 “Why the Mind is Not in the Brain,” International Conference on Phenomenological and Existential Issues in Modern Cognitive Science, San Marino, Italy.

9-23-91 “Randomized Controlled Trial of Nortriptyline for Chronic Severe Tinnitus,” 5th Annual NIMH Conference on Psychiatric Disorders in General Medical Settings,” Washington, D.C.

10-5-91 “Psychiatry and Privacy,” Conference on Privacy and the Professions, Ohio University, Athens, OH.

11-10-91 “Sedative/Hypnotic Taper in Chronic Pain Patients,” American Pain Society, 1991 Annual Meeting, New Orleans, LA..

5-2-92 “Proposals for Psychiatric Curriculum in General Internal Medicine,” Society for General Internal Medicine, 1992 Annual Meeting, Washington, D.C.

5-4-92 “Outpatient Consultation/Liaison Psychiatry: Success or Failure?” APA, 1992 Annual Meeting, Washington, D.C.

5-5-92 “Pharmacotherapy vs. Psychotherapy: Are Psychiatrists Polarized?” American Psychiatric Association, 1992 Annual Meeting, Washington, D.C.

5-7-92 “Antidepressant Treatment of Chronic Tinnitus: An RCT,” APA, 1992 Annual Meeting, Washington, D.C.

10-19-92 “Dizziness: Psychiatric and Ontologic Factors,” 6th Annual NIMH Conference on Psychiatric Disorders in General Medical Settings, Washington, D.C.

6-7-93 “Depression and Disability in Chronic Medical Illness,” Chronic Diseases and Changing Care Patterns in an Aging Society, Amsterdam, The Netherlands.

4-14-94 “Functional Status in Coronary Artery Disease,” American Psychosomatic Society, 1994 Annual Meeting, Boston MA.

5-24-94 “Coronary Disease and Functional Limitation: How Strong is the Relation?” American Psychiatric Association, 1994 Annual Meeting, Philadelphia, PA.

5-25-94 “Depression and Refusal of Life-Saving Medical Treatment,” American Psychiatric Association, 1994 Annual Meeting, Philadelphia, PA.

5-26-94 “Is It Possible to Abuse Prozac?” American Psychiatric Association, 1994 Annual Meeting, Philadelphia, PA.

7-19-94 “Functional Status in Coronary Artery Disease: Biomedical vs. Psychosocial Determinants,” Department of Medicine Grand Rounds, Oregon Health Sciences University, Portland, OR.

9-8-94 “Functional Status in Coronary Artery Disease: Biomedical or Psychosocial Determinants,” 8th Annual Meeting on Mental Disorders in General Medical Settings, NIMH Washington, D.C.

3-4-95 “Functional Status in Coronary Disease: Role of Anxiety and Depression,” American Psychosomatic Society, New Orleans, LA, 1995 annual meeting.

4-9-96 “Management of Somatization In Primary Care,” Sixth Kaiser Interregional Conference on Primary Care and Musculoskeletal Medicine, Kawai, Hawaii.

5-19-97 “Psychiatrists As Gatekeepers for Physician-Assisted Suicide,” Annual Meeting of the American Psychiatric Association, San Diego, CA.

8-11-97 “Psychosocial Factors and Functional Status in Coronary Heart Disease,” Cardiology Grand Rounds, University of Groningen, The Netherlands.

9-24-97 “Psychosocial Factors and Functional Status in Coronary Heart Disease,” Cardiology Grand Rounds, Royal Edinburgh Infirmary, University of Edinburgh, Edinburgh, Scotland.

9-26-97 “Psychosocial Factors and Functional Status in Coronary Heart Disease,” Institute of Psychiatry, Maudsley Hospital, Kings College Medical School, London, England.

11-14-97 “Should psychiatrists serve as gatekeepers for physician assisted suicide?” Academy of Psychosomatic Medicine Annual Meeting, San Diego, CA.

3-14-98 “The Problem of Pain in the Clinico-pathological Method,” Conference on Pain and Suffering in History, University of California, Los Angeles, CA.

3-19-98 “Physician-assisted Suicide: tough cases make bad laws?” Conference on Ethics in the 20th Century, Santa Clara University School of Law, Santa Clara, CA.

9-10-98 “Competence to Consent to Medical Treatment,” Ciberconferencia Medico-Legal Nationale, Clinica de Valli Lili, Cali, Columbia.

11-06-98 “Suffering and Cheating in Society,” American Pain Society, 1998 Annual Meeting, San Diego, CA.

8-21-99 “Philosophy and Pain,” Refresher Course, Ninth World Congress on Pain, International Association for the Study of Pain, Vienna, Austria.

8-23-99 “Pain and Disability,” Workshop, Ninth World Congress on Pain, International Association for the Study of Pain, Vienna, Austria.

8-23-99 “Attachment, Coping, Appraisal, and Disability in Chronic Pain Patients,” Poster, 9th World Congress on Pain, International Association for the Study of Pain, Vienna, Austria.

10-21-99 “Ethical Principles for Pain Management,” American Pain Society Annual Meeting, Ft. Lauderdale, FL.

10-22-99 “Attachment, Coping, Appraisal, and Disability in Chronic Pain Patients,” American Pain Society Annual Meeting, Ft. Lauderdale, FL.

11-18-99 “Effectiveness of Paroxetine and Problem-Solving Therapy for Younger Adults with Minor Depression or Dysthymia,” Academy of Psychosomatic Medicine Annual Meeting, New Orleans, LA.

11-20-99 “Effects of Anxiety and Depression on Symptoms and Function in Patients with Coronary Heart Disease: A Five-Year Prospective Study,” Academy of Psychosomatic Medicine Annual Meeting, New Orleans, LA.

3-14-00 “Patient Choice at the End of Life,” American Association for Geriatric Psychiatry Annual Meeting, Miami, FL.

4-4-00 “The Patient with Chronic Pain: A Psychiatrist’s Perspective,” Oregon Health Sciences University, Department of Psychiatry Grand Rounds, Portland, OR.

9-9-00 “Fibromyalgia: Psychiatric Controversies,” Oregon Health Sciences University, Center for Women’s Health, Portland, OR.

2-26-01 “Hope at the End of Life,”American Association of Geriatric Psychiatry, Annual Meeting, San Francisco, CA.

9-28-01 “Depression and Heart Failure Outcomes: Tertiary Care,” American Heart Association, 3rd Scientific Forum on Quality of Care and Outcomes Research, Washington, DC.

9-29-01 “Depression and Heart Failure Outcomes: Primary Care,” American Heart Association, 3rd Scientific Forum on Quality of Care and Outcomes Research, Washington, DC.

3-15-02 “Depression and Pain: Two Forms of Suffering in Primary Care,” American Pain Society 2002 Annual Meeting, Baltimore, MD.

 3-16-02 “Interpersonal Dimensions of the Pain Experience,” American Pain Society 2002 Annual Meeting, Baltimore, MD.

5-16-02 “Psychiatric Care at the End of Life,” University of British Columbia, Vancouver, BC.

8-13-02 “Managing Affective Disorders in Patients with Chronic Pain,” IASP Satellite Symposium on Pain and Negative Emotions, Salt Lake City, Utah.

8-20-02 “Depression and Pain in Primary Care,” World Congress on Pain, International Association for the Study of Pain, San Diego, CA.

10-11-02 “Depression and Heart Failure Outcomes: Tertiary Care,” American Heart Association, 3rd Scientific Forum on Quality of Care and Outcomes Research, Washington, DC.

10-11-02 “Depression and Heart Failure Outcomes: Primary Care,” American Heart Association, 3rd Scientific Forum on Quality of Care and Outcomes Research, Washington, DC.

7-16-03 “The New Subjective Medicine: Implications for Public Health,” National Center for Chronic Disease Prevention and Health Promotion Science Seminar, Centers for Disease Control and Prevention, Atlanta GA.

10-11-03 “How did health get to be objective?”, National Science Foundation Conference on Self as Scientific and Political Project, Penn State University, State College, PA

10-14-03 “Pain and Narrative as revealed through mindfulness meditation”, Conference on Narrative, Pain and Suffering”, Rockefeller Foundation Retreat Center, Bellagio, Italy

5-8-04 “Clinical Use of Placebos in Pain Management: ethical issues”, American Pain Society 2004 Annual Meeting, Vancouver BC Canada

5-16-04 “Depression Predicts Time to Combined Endpoint of Transplantation or Death in Outpatients with Advanced Heart Failure, American Heart Association, 5th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC.

9-8-04 “Ethical Issues in Pain Management After Spinal Cord Injury”, American Association of Spinal Cord Injury Psychologists and Social Workers, 2004 Annual Meeting, Las Vegas, NV

3-4-05 “Regular use of prescribed opioids: association with psychiatric disorders”, American Psychosomatic Society 2005 Annual Meeting, Vancouver BC

3-5-05 “Prevalence of depression in out-patients with heart failure: tertiary care vs primary care samples”, American Psychosomatic Society 2005 Annual Meeting, Vancouver BC

3-5-05 “Interpersonal predictors of chest pain in ischemic and non-ischemic patients”, American Psychosomatic Society 2005 Annual Meeting, Vancouver BC

3-31-05 “Regular use of prescribed opioids: association with psychiatric disorders”, American Pain Society, 2005 Annual Meeting, Boston, MA

3-31-05 “Attachment style and chest pain in patients undergoing myocardial perfusion imaging”, American Pain Society, 2005 Annual Meeting, Boston, MA

5-06-05 “Psychiatric and psychological assessment in patient with chronic pain”, Australia and New Zealand Faculty of Pain Medicine, 2005 Refresher Course, Auckland, NZ

5-07-05 “Chest pain and the mind: reconnecting the heart and the brain”, Australia and New Zealand College of Anesthesia 2005 Annual Meeting, Auckland, NZ

5-07-05 “Psychiatry of Angina”, Australia and New Zealand College of Anesthesia 2005 Annual Meeting, Auckland, NZ

5-07-05 “Somatization or sensitization?: is interoception the link?”, Australia and New Zealand College of Anesthesia 2005 Annual Meeting, Auckland, NZ

5-08-05 “Unrelieved and ‘unrelievable’ pain: what are our duties?”, Australia and New Zealand College of Anesthesia 2005 Annual Meeting, Auckland, NZ

10-21-05 “On the varieties of painful experience: is there one right to pain relief?”, American Society of Bioethics and Humanities 2005 Annual Meeting, Washington DC

5-04-06 “What does it mean to have a right to pain relief?”, American Pain Society, 2006 Annual Meeting, San Antonio, TX

5-05-06 “Depression, Anxiety and Problem Drug Use Predict Increased Use of Prescribed Opioids”, American Pain Society, 2006 Annual Meeting, San Antonio, TX

5-10-06 “Living in a Shrinking Box: life with advanced heart failure”, 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, DC

5-10-06 “Attachment Style and Angina in Patients Undergoing Myocardial Perfusion Imaging”, American Heart Association 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, DC

9-19-07 “Future planning in heart failure: engaging the patient”, Heart Failure Society of America 2007 Annual Meeting, Washington, D.C.

5-9-08 “Trends in use of opioids for non-cancer pain conditions in Blue Cross-Blue Shield and Medicaid insurance plans, 2000-2005: The TROUP Study”, American Pain Society, 2008 Annual Meeting, Tampa, FL

5-10-08 “Is opioid dose an ethical issue?”, American Pain Society, 2008 Annual Meeting, Tampa, FL

9-7-08 “Between psychiatry and palliative care”, Canadian Psychiatric Association, 2008 Annual Meeting, Vancouver, B.C.

3-10-09 “Pharmacoepidemiology of opioid use for chronic pain”, Pain and Suffering 2009 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-10-09 “Shared decision-making for opioid therapy for chronic pain”, Pain and Suffering 2009 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-17-10 “Pharmacoepidemiology of opioid use for chronic pain”, Pain and Suffering 2010 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-18-10 “Shared decision-making for opioid therapy for chronic pain”, Pain and Suffering 2010 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-11-11 “Emerging Epidemiology of Chronic Opioid Therapy”, Pain and Suffering 2011 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-10-11 “Communication beyond the prescription pad”, Pain and Suffering 2011 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-23-11 “Pain medicine and the Patient-Centered Medical Home, American Academy of Pain Medicine 2011 Annual Meeting, Washington, DC

3-24-11 “Patient-centered Chronic Pain Care: it’s not about the pain, American Academy of Pain Medicine 2011 Annual Meeting, Washington, DC

3-25-11 Mental health disorders and chronic opioid use among adolescents and young adults with chronic pain, American Academy of Pain Medicine 2011 Annual Meeting, Washington, DC

3-25-11 Long Term Chronic Opioid Therapy Discontinuation Rates From The TROUP Study, American Academy of Pain Medicine 2011 Annual Meeting, Washington, DC

3-25-11 Opioid Abuse and Dependence Among Individuals with Chronic non-Cancer Pain: The Role of Opioid Prescription, American Academy of Pain Medicine 2011 Annual Meeting, Washington, DC

3-11-12 “Risks of Chronic Opioid Therapy”, Pain and Suffering 2012 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-10-12 “Communication beyond the prescription pad”, Pain and Suffering 2012 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

5-9-12 “Discontinuation of chronic opioid therapy” American Pain Society, 2012 Annual Meeting, Honolulu, HI

5-10-12 “Incident opioid abuse diagnoses in patients receiving chronic opioid therapy”, American Pain Society, 2012 Annual Meeting, Honolulu, HI

8-30-12 “Opioid therapy for chronic pain: promises and perils, International Association for the Study of Pain, 2012 World Congress on Pain, Milan, Italy

3-8-13 “Policies to limit risks of Chronic Opioid Therapy”, Pain and Suffering 2013 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-8-13 “Principles of Cautious Opioid Prescribing”, Pain and Suffering 2013 Annual Symposium, The Foundation for Medical Excellence, Vancouver B.C.

3-13-14 “National Study of Opioid Use Among Veterans”, American Academy of Pain Medicine 2014 Annual Meeting, Phoenix, AZ

3-13-14 “Nationwide Study of Opioid Discontinuation Among Veterans”, American Academy of Pain Medicine 2014 Annual Meeting, Phoenix, AZ

3-14-14 “What Might Emerge from Under the Opioid Blanket?: mental health and substance abuse problems”, American Academy of Pain Medicine 2014 Annual Meeting, Phoenix, AZ

5-11-15 “Are opioids ever appropriate for the treatment of chronic pain”, American Pain Society 2015 Fundamentals Course, Palm Springs CA

5-12-15 “Trends in Opioid Dosing Among of Washington State Medicaid Patients Before and After Opioid Dosing Guideline Implementation”, American Pain Society 2015 Annual Meeting, Palm Springs CA

5-15-15 “Tapering prescription opioids: challenges, risks, and negotiations”, American Pain Society 2015 Annual Meeting, Palm Springs CA

5-11-16 “Collaborative care for improving pain and depression care in a multiple sclerosis specialty clinic: implementation and preliminary findings from a randomized controlled trial”, American Pain Society 2016 Annual Meeting, Austin, TX.

5-11-16 “Prevalence of post-traumatic stress disorder and its association with outcome measures in a general chronic pain population”, American Pain Society 2016 Annual Meeting, Austin, TX.

5-13-16 “Pain intensity—wrong chronic pain metric?”, American Pain Society 2016 Annual Meeting, Austin, TX.

5-21-16 “The chemistry and psychiatry of opioid tapering”, 5th Annual Thoughtful Approach to Pain Management, Continuing Medical Education of Southern Oregon, Medford, OR

5-6-17 “Does the patient with complex chronic pain have physical pain, mental pain, or centralized pain… and does it make a difference? Oregon Pain Group 6th Annual Conference, Ashland, OR

5-16-17 TelePain: Improving primary care pain management, American Pain Society 2017 Annual Meeting, Pittsburgh, PA

 Doorenbos, A., Eaton, L., Theodore, B., Sullivan, M., Robinson, J., Rapp, S., & Tauben, D

11-10-17 “Ethics of Pain Care: what do we owe to patients with chronic pain?”, Pain Care in a Time of Transition, Virginia Mason Continuing Medical Education, Seattle WA

3-23-18 “Depression in patients with heart failure: is it useful to treat the blues?” Cardiology Grand Rounds, University of Washington, Seattle, WA

4-28-18 “Unintended Prolonged Opioid Use; the role of patient self-selection”, American Academy of Pain Medicine Annual Meeting, Vancouver, BC

5-1-18 “Randomized trial of opioid taper support: results and next steps”, RTI International, Research Triangle Park, NC

5-4-18 “Between suffering and survival: understanding dynamic links among physical pain, social pain and addiction”, American Academy of Psychoanalysis and Dynamic Psychiatry, New York, NY

6-1-18 “Understanding Adverse Selection: the role of mental health disorders in long-term opioid therapy, NIH Pain Symposium, Washington, DC

11-3-18 “Hierarchical Attention-Based Prediction Model for Discovering the Persistence of Chronic Opioid Therapy from a large Clinical Dataset”, AMIA Annual Meeting, San Francisco, CA

9-12-18 “Opioid Therapy Risk Mitigation in the US”, World Congress on Pain, International Association for the Study of Pain, Boston, MA

9-14-18 “Interventions to promote tapering long-term opioid therapy: a review of the evidence” World Congress on Pain, International Association for the Study of Pain, Boston, MA

10-11-18 “Investigating Opioids Inside and Out to Better Understand our Current Epidemic”, Sixth Annual Carus Lecture in Philosophy, Concordia College, Moorhead, MN

11-9-18 “Pain and Opioids: damage and danger, mechanism and meaning, BC Pain Research Network Conference, *Pain, Affect and Opioids,* University of British Columbia, Vancouver BC

11-15-18 “Understanding opioid dependence: a significant harm of long-term opioid therapy”, 2nd Annual Covington Lecture on Chronic Pain, Cleveland Clinic, Cleveland OH

11-16-18 “Understanding adverse selection: the role of mental health in opioid therapy for chronic pain”, Psychiatry Grand Rounds, Cleveland Clinic, Cleveland, OH

5-2-19 “Prescribing Opioids to Older Adults with Chronic Pain:  What are the Perils?”, American Geriatric Society Annual Meeting, Portland OR

6-2-19 “Patient As Agent of Health and Health Care”, Congress 2019, Canadian Philosophical Association, University of British Columbia, Vancouver, BC